Page last updated: 2024-12-05

gemfibrozil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Gemfibrozil is a fibrate drug used to treat high cholesterol. It lowers triglyceride levels and raises high-density lipoprotein (HDL) cholesterol, known as good cholesterol. It works by activating a nuclear receptor called peroxisome proliferator-activated receptor alpha (PPARα), which regulates lipid metabolism. Gemfibrozil is synthesized from 2,2-dimethylpropionic acid and 4-chlorophenoxy acetic acid through a series of chemical reactions. Gemfibrozil is studied for its potential to reduce the risk of cardiovascular disease. It is also being investigated for its potential to treat other conditions, such as diabetes and certain types of cancer. '

Cross-References

ID SourceID
PubMed CID3463
CHEMBL ID457
CHEBI ID5296
SCHEMBL ID4813
MeSH IDM0023484

Synonyms (248)

Synonym
STK618740
AB00052003-15
BRD-K11129031-001-05-1
KBIO1_000138
DIVK1C_000138
2,2-dimethyl-5-(2,5-xylyloxy)valeriansaeure
2,2-dimethyl-5-(2,5-xylyloxy)valeric acid
gemfibrozilum
gemfibrozilo
CHEBI:5296 ,
lipur
2,2-dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure
lipozid
lopid
innogem
ci-719
5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid
SPECTRUM_000825
IDI1_000138
BPBIO1_000251
PRESTWICK_637
cas-25812-30-0
NCGC00016794-01
SPECTRUM5_001991
BSPBIO_000227
PRESTWICK2_000214
PRESTWICK3_000214
pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-
teva-a
5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid
5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
NCGC00022722-03
AB00052003
MLS001055364
normolip
wl-gemfibrozil
lipazil
lanaterom
lifibron
gemfibrosil
renabrazin
hipolixan
synbrozil
gemlipid
ci 719
innogen
lipigem
elmogan
tentroc
gem-s
gozid
bolutol
apo-gemfibrozil
gemfibromax
reducel
regulip
gemfibril
einecs 247-280-2
cholespid
brozil
hidil
sinelip
ccris 318
decrelip
pilder
micolip
gevilon uno
lipizyl
gemd
progemzal
fetinor
jezil
litarek
gemfibrozilum [inn-latin]
gemnpid
fibratol
fibrocit
gemfibrozilo [inn-spanish]
trialmin
valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)-
taborcil
clearol
ipolipid
lipira
brn 1881200
low-lip
ausgem
25812-30-0
gemfibrozil ,
C07020
DB01241
D00334
lopid (tn)
gemfibrozil (jan/usp/inn)
SPECTRUM5_000750
NCGC00022722-04
NCGC00022722-06
NCGC00022722-05
NCGC00022722-07
MLS000028421 ,
smr000058393
KBIOSS_001305
KBIO2_003873
KBIO3_001280
KBIOGR_000964
KBIO2_006441
KBIO2_001305
SPECTRUM2_001097
SPECTRUM3_000440
SPBIO_002148
PRESTWICK1_000214
SPECTRUM4_000562
SPBIO_001174
PRESTWICK0_000214
NINDS_000138
SPECTRUM1500313
BSPBIO_002060
NCGC00016794-02
HMS2090K14
AC-4225
HMS2091H11
AKOS001606691
nsc-757024
CHEMBL457 ,
HMS500G20
bdbm50110590
sr-01000000056
SR-01000000056-6
HMS1568L09
HMS1920B07
cpd000058393
NCGC00016794-09
HMS3259M12
HMS2095L09
NCGC00256601-01
tox21_302784
dtxsid0020652 ,
dtxcid20652
tox21_201997
NCGC00259546-01
A818037
G0368
2,2-dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid
BBL010807
2,2-dimethyl-5-(2,5-dimethylphenoxy)valeric acid
nsc757024
pharmakon1600-10500313
tox21_110613
HMS2230H24
CCG-40111
NCGC00016794-04
NCGC00016794-05
NCGC00016794-08
NCGC00016794-03
NCGC00016794-06
NCGC00016794-10
NCGC00016794-11
NCGC00016794-07
q8x02027x3 ,
unii-q8x02027x3
gemfibrozil [usan:usp:inn:ban]
hsdb 7735
nsc 757024
genlip
gen-fibro
gemcor
FT-0626641
NCGC00016794-14
AB03034
S1729
gtpl3439
gemfibrozil [usp monograph]
gemfibrozil [jan]
gemfibrozil [inci]
gemfibrozil [mart.]
gemfibrozil [vandf]
gemfibrozil [usp-rs]
gemfibrozil [mi]
gemfibrozil [iarc]
gemfibrozil [ep monograph]
gemfibrozil [hsdb]
2,2-dimethyl-5-(2,5-xylyloxy) valeric acid
gemfibrozil [inn]
gemfibrozil [usan]
gemfibrozil [orange book]
gemfibrozil [who-dd]
DL-414
HY-B0258
2,2-dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid
NC00565
SCHEMBL4813
tox21_110613_1
NCGC00016794-13
KS-5192
AB00052003-16
MLS006011850
W-107216
2,2-dimethyl-5-(2,5-zlyloxy)valeric acid
4tx ,
gemfibrozil, british pharmacopoeia (bp) reference standard
AB00052003_18
OPERA_ID_1658
AB00052003_17
mfcd00079335
gemfibrozil, analytical standard
SR-01000000056-3
gemfibrozil, united states pharmacopeia (usp) reference standard
HMS3655C06
EN300-97098
gemfibrozil, european pharmacopoeia (ep) reference standard
gemfibrozil for system suitability, european pharmacopoeia (ep) reference standard
gemfibrozil, pharmaceutical secondary standard; certified reference material
SR-01000000056-7
SR-01000000056-4
SBI-0051391.P003
HMS3712L09
SW196802-3
5-(2,5-dimethylphenoxy)-2,2-
dimethylpentanoic acid
BCP08437
Q384295
gemfibrozil (lopid)
FT-0700924
gemfibrozil,(s)
114413-98-8
D83091
SY052512
2,2-dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid, 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid, 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic aci
YSSJ5501
gemfibrozil for system suitability
gemfibrozil 100 microg/ml in acetonitrile
2,2-dimethyl-5-(2,5-dimethylphenoxy)valeriansaure
gemfibrozil (usp monograph)
gemfibrozil (ep monograph)
2,2-dimethyl-5-(2,5-xylyloxy)valeriansaure
cl-719
gemfibrozilum (inn-latin)
gemfibrozilo (inn-spanish)
5-(2,5-dimethyphenoxy)-2,2-dimethylpentanoic acid
gemfibrozil (usan:usp:inn:ban)
c10ab04
gemfibrozil (mart.)
gemfibrozil (iarc)
gemfibrozil (usp-rs)
CS-0694895
gemfibrozil (standard)
HY-B0258R
Z1259021151

Research Excerpts

Overview

Gemfibrozil (GEM) is an orally administered lipid-regulating fibrate derivative drug sold under the brand name Lopid. It is a hypolipidemic agent, which is effective in reducing serum cholesterol and triglyceride levels.

ExcerptReferenceRelevance
"Gemfibrozil (GFZ) is a lipid-lowering drug with several other effects, such as antioxidant and anti-inflammatory activities. "( Gemfibrozil, a lipid-lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d-galactose-induced aging mice.
Borisov, VV; Ehsani, V; Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanshahi, J; Kaeidi, A; Khajehasani, F; Movahedinia, S; Zamanian, MY, 2022
)
3.61
"Gemfibrozil (GEM) is an orally administered lipid-regulating fibrate derivative drug sold under the brand name Lopid"( Structural Analysis of Human Serum Albumin in Complex with the Fibrate Drug Gemfibrozil.
Angelini, A; Cendron, L; De Toni, L; Liberi, S; Linciano, S; Moro, G, 2022
)
2.39
"Gemfibrozil (GEM) is a hypolipidemic agent, which is effective in reducing serum cholesterol and triglyceride levels. "( A Comprehensive Study of Gemfibrozil Complexation with β-Cyclodextrins in Aqueous Solution Using Different Analytical Techniques.
González-Gaitano, G; Martínez-Ohárriz, MC; Vélaz, I; Zornoza, A, 2022
)
2.47
"Gemfibrozil (GFZ) is a medication of the fibrate category with agonistic effects on peroxisome proliferator-activated receptor-α (PPAR-α) and is effective for hypertriglyceridemia and mixed dyslipidemia. "( Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging.
Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanipour, M; Soltani, A; Tadayon, S; Zamanian, MY, 2023
)
3.8
"Gemfibrozil is a drug that has been used for over 40 years to lower triglycerides in blood. "( Gemfibrozil-Induced Intracellular Triglyceride Increase in SH-SY5Y, HEK and Calu-3 Cells.
Bachmann, CM; Erhardt, T; Grimm, HS; Grimm, MOW; Hartmann, T; Janitschke, D; Lauer, AA, 2023
)
3.8
"Gemfibrozil is a fibrate that acts via peroxisome proliferator-activated receptor alpha to promote changes in lipid metabolism and decrease serum triglyceride levels."( Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice.
Araujo, RC; Arruda, AC; Budu, A; Estrela, GR; Fock, RA; Freitas-Lima, LC; Paredes-Gamero, EJ; Perilhão, MS; Torquato, HFV; Wasinski, F, 2020
)
2.72
"Gemfibrozil is a fibrate drug used widely for dyslipidemia associated with atherosclerosis. "( Species-related exposure of phase II metabolite gemfibrozil 1-O-β-glucuronide between human and mice: A net induction of mouse P450 activity was revealed.
Dai, M; Lin, H; Lin, J; Liu, A; Luo, M; Xie, M; Yang, J, 2017
)
2.15
"Gemfibrozil (GEM) is a lipid-lowering drug with a number of biological properties such as anti-inflammatory and antioxidant activities."( Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats.
Aminzadeh, A; Fatemi, I; Goudarzi, M; Haybar, H; Kalantar, M; Khodayar, MJ; Mehrzadi, S, 2019
)
1.64
"Gemfibrozil (GFZ) is a derivative of fibric acid and is used in the treatment of dyslipidemia. "( UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers.
Cestari, RN; de Oliveira, RDR; Lanchote, VL; Rocha, A, 2019
)
2.27
"Gemfibrozil is a widely used hypolipidemic and triglyceride lowering drug. "( Genomic, Proteomic, and Metabolite Characterization of Gemfibrozil-Degrading Organism Bacillus sp. GeD10.
Gough, HL; Kjeldal, H; Nielsen, JL; von Bergen, M; Wissenbach, DK; Zhou, NA, 2016
)
2.12
"Gemfibrozil is a lipid-modifying agent that belongs to the fibric acid derivative class. "( Gemfibrozil in Combination with Statins-Is It Really Contraindicated?
Morris, PB; Saseen, JJ; Wiggins, BS, 2016
)
3.32
"Gemfibrozil (GFZ) is a relatively persistent pollutant in surface-water environments and it is rather recalcitrant to biological degradation. "( Modelling the photochemical attenuation pathways of the fibrate drug gemfibrozil in surface waters.
Fabbri, D; Maurino, V; Minella, M; Minero, C; Vione, D, 2017
)
2.13
"Gemfibrozil is a practically water-insoluble, high-dose drug. "( Investigation on different levels of in vitro-in vivo correlation: gemfibrozil immediate release capsule.
Ardakani, YH; Baluchestani, M; Hakemi, L; Mirfazaelian, A; Rouini, MR, 2008
)
2.02
"Gemfibrozil (GEM) is a fibrate drug consistently found in effluents from sewage treatment plants. "( The fibrate drug gemfibrozil disrupts lipoprotein metabolism in rainbow trout.
Mennigen, JA; Moon, TW; Prindiville, JS; Weber, JM; Zamora, JM, 2011
)
2.15
"Gemfibrozil is a RORγ inhibitor that was inactive against Mtb cells."( Is RORγ a therapeutic target for treating Mycobacterium tuberculosis infections?
Baures, PW, 2012
)
1.1
"Gemfibrozil is a fibrate that has been detected in wastewater treatment plant influents, effluents, and drinking water."( Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas).
Ankley, GT; Durhan, EJ; Jensen, KM; Kahl, MD; Makynen, EA; Skolness, SY; Villeneuve, DL, 2012
)
1.49
"Gemfibrozil is a PPAR-α ligand that inhibits the progression of atherosclerosis in insulin resistance type 2 diabetes mellitus (IR type 2 DM). "( Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.
Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP, 2013
)
3.28
"Gemfibrozil is a lipid-regulating active substance. "( [Preparation and investigation of gemfibrozil + dimethyl-beta-cyclodextrin products and solid dosage forms].
Aigner, Z; Eros, I; Hassan, BH; Hódi, K; Kása, P, 2005
)
2.05
"Gemfibrozil is a lipid-regulating agent widely used in patients at risk of coronary disease. "( Toxicological effects of the lipid regulator gemfibrozil in four aquatic systems.
Cameán, AM; Jos, A; López-Artíguez, M; Repetto, G; Salguero, M; Zurita, JL, 2007
)
2.04
"Gemfibrozil is a widely used hypolipidemic drug in humans that causes peroxisome proliferation and hepatocarcinogenesis in rodents. "( Gemfibrozil-induced peroxisome proliferation and hepatomegaly in male F344 rats.
Cattley, RC; Miller, RT; Sausen, PJ; Teets, VJ; Voss, KS, 1995
)
3.18
"Gemfibrozil is an effective and safe drug in patients with coronary heart disease (CHD) and the high triglyceride-low HDL cholesterol trait."( Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
Kastelein, JJ; Knipscheer, HC; Mulder, WJ; Nurmohamed, MT; Plaat, B; Pruijs, HJ; Van den Ende, A, 1994
)
3.17
"Gemfibrozil is an effective hypotriglyceridemic agent. "( Increase in intracellular triglyceride synthesis induced by gemfibrozil.
Baldo, A; Cianflone, K; Sniderman, AD, 1994
)
1.97
"As gemfibrozil is a potent inhibitor of fatty acid elongation in vitro (Sánchez et al., FEBS Lett 300: 89-92, 1992), the inhibition of this enzyme system by gemfibrozil treatment could be responsible for the observed results in vivo."( Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation.
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Vázquez, M, 1993
)
2.24
"Gemfibrozil is a widely used drug that elevates plasma HDL and lowers triglycerides and LDL. "( Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2).
Chuang, MY; Jin, FY; Kamanna, VS; Kashyap, ML; Morgan, K, 1996
)
3.18
"Gemfibrozil is a fibrate lipid-lowering agent that is extensively metabolized to an acyl glucuronide conjugate in humans."( Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide.
Fairchild, BA; Pannall, PR; Sallustio, BC, 1997
)
1.25
"Gemfibrozil is an antihyperlipidaemia agent used in therapy to reduce the occurrence of coronary heart disease. "( The priming effect of gemfibrozil on reactive oxygen metabolism of phagocytic leucocytes. An intriguing side effect.
De Sole, P; Fresu, R; Giardina, B; Nocca, G; Scatena, R; Zuppi, C, 1997
)
2.05
"Gemfibrozil is a widely used drug prescribed to elevate serum high-density lipoprotein (HDL) cholesterol levels and lower triacylglycerols. "( Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet.
Imaizumi, K; Nagao, K; Nakagiri, H; Sakono, M; Sato, M; Yoshida, S, 1998
)
3.19
"Gemfibrozil (GEM) is a clofibrate analog used to treat moderate to severe hypertriglyceridemias. "( Isolation and identification of novel metabolites of gemfibrozil in rat urine.
Burgess, JP; Coleman, DP; Dix, KJ; Jeffcoat, AR; Scheffler, NM; Thomas, BF, 1999
)
2
"Gemfibrozil is an effective drug in the treatment of hypertriglyceridemia and its effects on morbidity and mortality seem out of proportion to its lipid lowering actions. "( Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia.
Bibbs, D; Dang, AQ; Faas, FH; Reeves, C; Smith, WG; Wang, J, 2002
)
3.2
"Gemfibrozil is a fibrate drug."( [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C, 1992
)
1.22
"Gemfibrozil (G) is a widely used and highly effective fibric acid derivative. "( Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
Bertoli, M; Calabresi, L; Chiesa, G; Franceschini, G; Gianfranceschi, G; Maderna, P; Sirtori, CR; Vaccarino, V, 1992
)
2.05
"Gemfibrozil is a lipid-regulating agent which is generically classified as a fibric acid derivative, but which exhibits different pharmacological effects from other such drugs. "( Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.
Todd, PA; Ward, A, 1988
)
3.16
"Gemfibrozil (Lopid) is a new plasma lipid-regulating drug that decreases very low and low density lipoprotein (VLD/LDL) and increases high density lipoprotein (HDL) concentrations in man. "( Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
Krause, BR; Newton, RS, 1985
)
1.94
"Gemfibrozil is a potent lipid regulating drug whose major effects are to increase plasma high density lipoproteins (HDL) and to decrease plasma triglycerides (TG) in a wide variety of primary and secondary dyslipoproteinemias. "( Mechanism of action of gemfibrozil on lipoprotein metabolism.
Gartside, PS; Hynd, BA; Kashyap, ML; Saku, K, 1985
)
2.02

Effects

Gemfibrozil has shown efficacy in the treatment of patients with type IIa, IIb, III, IV or V dyslipidaemia or hypoalphalipoproteinaemia. It has been shown to have beneficial effects in the primary and secondary prevention of atherosclerosis.

ExcerptReferenceRelevance
"Gemfibrozil has shown efficacy in an animal model of NCL known as CLN2 (late infantile classic juvenile) and has been shown to be safe for lowering lipids in children."( Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.
Kim, K; Kleinman, HK; Lee, HJ; Pahan, K, 2017
)
1.46
"Gemfibrozil has recently been shown to exert sGC activating effects in vitro."( Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation.
Benke, K; Hartyánszky, I; Horváth, EM; Kökény, G; Mátyás, C; Merkely, B; Németh, BT; Oláh, A; Radovits, T; Ruppert, M; Sayour, AA; Szabó, G; Szabolcs, Z, 2017
)
1.45
"Gemfibrozil has been suggested as a sensitive cytochrome P450 2C8 (CYP2C8) inhibitor for clinical investigation by the U.S. "( Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
Bi, YA; Kimoto, E; Lin, J; Rodrigues, AD; Varma, MV, 2015
)
2.14
"Gemfibrozil has no effect on the pharmacokinetics of zafirlukast, indicating that CYP2C8 does not play a significant role in the elimination of zafirlukast."( The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Backman, JT; Karonen, T; Neuvonen, PJ, 2011
)
2.13
"Yet, gemfibrozil has been shown to inhibit Mtb growth in macrophages, supporting the hypothesis that RORγ inhibitors could show therapeutic benefit in Mtb infection.(7)."( Is RORγ a therapeutic target for treating Mycobacterium tuberculosis infections?
Baures, PW, 2012
)
0.83
"A gemfibrozil glucuronide has been reported to show time-dependent inhibition of cytochrome P450 2C8."( The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver.
Kamimura, H; Mano, Y; Usui, T, 2007
)
1.14
"Gemfibrozil has the effect of increasing the area under the concentration-time curve (AUC) of repaglinide eightfold."( The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Backman, JT; Kalliokoski, A; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A, 2008
)
1.43
"Gemfibrozil has shown efficacy in the treatment of patients with type IIa, IIb, III, IV or V dyslipidaemia or hypoalphalipoproteinaemia, especially in patients with elevated triglyceride and low HDL cholesterol levels."( Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
Barradell, LB; Spencer, CM, 1996
)
2.46
"Gemfibrozil has shown beneficial effects as a lipid lowering agent; however, some proactivating effects on platelet function in vitro have been described."( Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk.
Alfón, J; Badimon, L; Berrozpe, M; Gaffney, P; Palazón, CP; Royo, T, 1998
)
1.28
"Gemfibrozil has been shown to have beneficial effects in the primary and secondary prevention of atherosclerosis. "( Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia.
Alfón, J; Badimon, L; Berrozpe, M; Royo, T, 2000
)
2.15

Actions

Gemfibrozil clearly plays a role in the modulation of the anionic flux in erythrocytes. It causes a strong increment of anions transport when the RBCs are in the high-oxygenation state (HOS)

ExcerptReferenceRelevance
"Gemfibrozil may increase cholesterol synthesis by activating the pathway from acetate to mevalonate."( Effects of peroxisome proliferators gemfibrozil and clofibrate on syntheses of dolichol and cholesterol in rat liver.
Hashimoto, F; Hayashi, H; Ikeda, M; Shiota, Y, 2003
)
1.32
"Gemfibrozil does not increase the plasma concentrations of the parent zopiclone. "( The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
Backman, JT; Neuvonen, PJ; Tornio, A, 2006
)
2.1
"Gemfibrozil clearly plays a role in the modulation of the anionic flux in erythrocytes; in fact it causes a strong increment of anions transport when the RBCs are in the high-oxygenation state (HOS)."( Influence of gemfibrozil on sulfate transport in human erythrocytes during the oxygenation-deoxygenation cycle.
Bellocco, E; Colucci, D; Ficarra, S; Galtieri, A; Giardina, B; Kotyk, A; Lagana', G; Russo, A; Scatena, R; Tellone, E, 2008
)
1.44
"The gemfibrozil-dependent increase in the flux of labeled diacylglycerol into phosphatidylcholine is rapid (15 min) and associated with a 2-fold increase in membrane-bound phosphocholine cytidylyltransferase activity."( An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion.
Bush, SR; Koch, JC; Lamb, RG, 1993
)
1
"Gemfibrozil may inhibit the synthetic pathway of dolichol, at least from mevalonate."( Changes in isoprenoid lipid synthesis by gemfibrozil and clofibric acid in rat hepatocytes.
Hashimoto, F; Hayashi, H; Taira, S, 2000
)
1.29
"Gemfibrozil caused an increase in HDL cholesterol."( [Gemfibrozil in the treatment of hyperlipidemia].
Lin, WH; Song, YM; Wang, JJ; Wang, YS, 1989
)
1.91

Treatment

Gemfibrozil treatment led to anemia seven days after the first administration. We found reduced levels of hemoglobin, as well as red blood cells, white blood cells and a reduced percentage of hematocrits. Treatment increased LDL size and lowered numbers of LDL particles (-5%) while raising numbers of HDL particles (10%) and small HDL subclass particles (21%)

ExcerptReferenceRelevance
"Gemfibrozil treatment led to anemia seven days after the first administration of the drug; we found reduced levels of hemoglobin, as well as red blood cells, white blood cells and a reduced percentage of hematocrits."( Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice.
Araujo, RC; Arruda, AC; Budu, A; Estrela, GR; Fock, RA; Freitas-Lima, LC; Paredes-Gamero, EJ; Perilhão, MS; Torquato, HFV; Wasinski, F, 2020
)
2.72
"Gemfibrozil treatment also restored CUMS-induced inhibition of the hippocampal BDNF signaling pathway."( Gemfibrozil has antidepressant effects in mice: Involvement of the hippocampal brain-derived neurotrophic factor system.
Gu, QY; Jiang, B; Ni, YF; Wang, FY; Wang, H; Wang, JL; Wang, YJ, 2018
)
2.64
"Gemfibrozil treatment restored the endothelium-dependent responses to acetylcholine in diabetic rats."( Effects of gemfibrozil treatment on vascular reactivity of streptozotocin-diabetic rat aorta.
Akin, FB; Ozansoy, G, 2004
)
1.43
"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively."( Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil.
Brunner, J; Lin, JH; Michel, K; Mu, L; Prueksaritanont, T; Qiu, Y; Richards, KM, 2005
)
1.06
"Gemfibrozil treatment increased LDL size and lowered numbers of LDL particles (-5%) while raising numbers of HDL particles (10%) and small HDL subclass particles (21%)."( Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Bloomfield, HE; Collins, D; Freedman, DS; McNamara, JR; Otvos, JD; Robins, SJ; Schaefer, EJ; Shalaurova, I, 2006
)
1.26
"Gemfibrozil treatment decreased the number of T-bet-positive T cells and increased the number of GATA3-positive T cells in spleen of donor mice."( Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha.
Dasgupta, S; Hartley, DM; Jana, M; Pahan, K; Roy, A, 2007
)
2.5
"Gemfibrozil treatment was associated with 3% to 6% decreases in the small, lipid-poor prebeta-1 HDL and in the large, lipid-rich alpha-1 and alpha-2 HDL and with increases in the small alpha-3 (3%) and prealpha-3 (16%) HDLs."( Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Asztalos, BF; Bloomfield, HE; Collins, D; Horvath, KV; Robins, SJ; Schaefer, EJ, 2008
)
1.45
"Gemfibrozil treatment in non-PiZ patients also resulted in a reduction of alpha 1-AT activity which could be reproduced in vitro."( An interaction between Gemfibrozil and alpha 1-antitrypsin.
Eriksson, S; Janciauskiene, S, 1994
)
1.32
"Gemfibrozil treatment in patients with familial dysbetalipoproteinemia resulted in a marked reduction of the concentrations of large VLDL, small VLDL, and IDL, and an increase in the levels of HDL, apo A-I, and apo A-II. "( Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
Leuven, JA; Smelt, AH; van 't Hooft, FM; van der Laarse, A; Vroom, TF; Zhao, SP, 1994
)
1.96
"Gemfibrozil treatment significantly reduces both plasma lipids and apoB, apoC-III and apoE concentrations in patients with moderately advanced renal insufficiency. "( Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
Alaupovic, P; Attman, PO; Knight-Gibson, C; Kron, B; Larsson, R; Mulec, H; Samuelsson, O; Weiss, L, 1997
)
2.14
"Gemfibrozil treatment lowered plasma triglycerides and both total and very low-density lipoprotein (VLDL)-cholesterol (P < 0.001 for all by ANOVA), whereas high-density lipoprotein (HDL)-cholesterol increased (P < 0.001). "( Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia.
Aberg, F; Angelin, B; Appelkvist, EL; Bröijersén, A; Dallner, G; Eriksson, M; Hjemdahl, P, 1998
)
3.19
"Gemfibrozil treatment of men with combined hyperlipidaemia reduces serum antioxidant levels to the levels seen in healthy normolipidaemic men. "( Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia.
Aberg, F; Angelin, B; Appelkvist, EL; Bröijersén, A; Dallner, G; Eriksson, M; Hjemdahl, P, 1998
)
3.19
"Gemfibrozil treatment was also withdrawn significantly more frequently due to a possible adverse reaction compared with the other two drugs."( A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999
)
1.26
"Gemfibrozil treatment significantly decreased plasma triglyceride concentration from 316+/-84 to 214+/-82 mg/dl (P < 0.001), whereas with placebo triglyceride levels increased from 318 + 93 to 380 + 217 mg/dl."( The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
Avogaro, A; Catapano, A; Miola, M; Piliego, T; Tiengo, A, 1999
)
1.39
"Gemfibrozil treatment alone reduced the CK increments 8 hours postexercise by 47% and the FABP increments 1 and 8 hours postexercise by 83% and 101%, respectively (all P < .05)."( Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention.
De Bruin, TW; Eekhoff, EM; Erkelens, DW; Glatz, J; Smit, JW, 1999
)
1.02
"Gemfibrozil treatment did not affect plasma fibrinolysis or fibrinogen levels, despite marked reduction of plasma triglycerides and improvement of the insulin sensitivity associated with triglyceride normalization."( Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.
Alessandrini, P; Bittolo Bon, G; Bonfardeci, G; Cimminiello, C; Colombo, L; Mannucci, L; Mussoni, L; Nenci, G; Notarbartolo, A; Parise, P; Pazzucconi, F; Piliego, T; Scafidi, V; Sirtori, C; Tremoli, E, 2000
)
1.42
"Gemfibrozil treatment of hypertriglyceridemic patients reduced the residence times of 3H-TO and 14C-CO, respectively, by 46% (P=0.003) and 53% (P=0.008)."( The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia.
Maranhão, RC; Ramires, JA; Santos, RD; Schreiber, R; Spósito, AC; Ventura, LI, 2001
)
1.38
"Gemfibrozil treatment normalised the defects in chylomicron-like emulsion catabolism observed in endogenous hypertriglyceridemia patients."( The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia.
Maranhão, RC; Ramires, JA; Santos, RD; Schreiber, R; Spósito, AC; Ventura, LI, 2001
)
2.11
"Gemfibrozil treatment had no effect on blood glucose, plasma insulin and vessel antioxidant enzyme activity of diabetic animals."( Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats.
Akin, B; Aktan, F; Karasu, C; Ozansoy, G, 2001
)
1.42
"In gemfibrozil treated rats and hamsters, a decrease in alpha-tocopherol content and an increase in DT-diaphorase activity were observed."( Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters.
Cunningham, ML; Glauert, HP; O'Brien, ML; Spear, BT; Twaroski, TP, 2001
)
0.82
"Gemfibrozil treatment lowered levels of lipid peroxides in both VLDL and HDL particles."( Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.
Chen, MF; Hsu, HC; Lee, YT; Yeh, HT, 2001
)
1.43
"Gemfibrozil treatment resulted in a decrease in plasma total triglyceride levels and the triglyceride content of all lipoproteins. "( Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
Chen, MF; Hsu, HC; Lee, YT; Wang, TD; Yeh, HT, 2001
)
3.2
"Gemfibrozil treatment was associated with a rise in the relative biliary concentration of cholesterol from 5.6 +/- 0.4 to 6.9 +/- 0.5 molar percent (P less than 0.01), and a parallel decrease in the relative concentration of bile acids, resulting in an increased cholesterol saturation of the bile, from 77 +/- 5 to 90 +/- 6% (P less than 0.05)."( Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids.
Angelin, B; Berglund, L; Ericsson, S; Lindmark, M; Odman, B, 1991
)
2.45
"Gemfibrozil treatment produced a marked reduction in plasma triglyceride (51%, P = 0.001) and a 15% decrease in plasma total cholesterol (P = 0.003)."( Treatment of nephrotic hyperlipoproteinemia with gemfibrozil.
Cheung, AK; Ellis-Benigni, K; Groggel, GC; Wilson, DE, 1989
)
1.25
"Pretreatment with gemfibrozil (30 mg/kg) for 7 days moderately but significantly reduced infarct size at 24 h after MCAO."( Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice.
Guo, Q; Liu, X; Namura, S; Wang, G, 2009
)
1.07
"The treatment of gemfibrozil solutions with sodium hypochlorite yielded a 4'-chlorinated gemfibrozil analog (chlorogemfibrozil)."( Analytical and biological characterization of halogenated gemfibrozil produced through chlorination of wastewater.
Beni, S; Bulloch, DN; Forsgren, KL; Larive, CK; Lavado, R; Schlenk, D, 2012
)
0.95
"Treatment with gemfibrozil, a drug that specifically reduces triglyceride levels, reversed both hypertriglyceridemia and impaired leptin transport."( Triglycerides induce leptin resistance at the blood-brain barrier.
Banks, WA; Coon, AB; Moinuddin, A; Morley, JE; Nakaoke, R; Robinson, SM; Shultz, JM, 2004
)
0.66
"Treatment with gemfibrozil did not affect the distribution of SV/SVA, but rather affected the elimination of SVA and the SV/SVA interconversion processes."( Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil.
Brunner, J; Lin, JH; Michel, K; Mu, L; Prueksaritanont, T; Qiu, Y; Richards, KM, 2005
)
0.89
"Treatment with gemfibrozil, compared with placebo, significantly reduced fasting plasma triglycerides (difference from placebo +/- SE; -50.2 +/- 20.6 mg/dl, p = 0.02), total cholesterol (-16.4 +/- 7.5 mg/dl, p = 0.04), apolipoprotein B (-16.1 +/- 5.5 mg/dl, p = 0.006), very LDL mass of S(f) 20 to 400 (-50.8 +/- 24.1 mg/dl, p = 0.02), S(f) 20 to 60 (-17.5 +/- 8.5 mg/dl, p = 0.05), S(f) 60 to 100 (-16.2 +/- 8.1 mg/dl, p = 0.05), and increased peak S(F) (0.48 +/- 0.27 Svedberg, p = 0.08)."( Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
Berneis, KK; Rizzo, M; Superko, HR; Williams, PT; Wood, PD, 2005
)
2.11
"Treatment with gemfibrozil modifies acyl composition of hepatic microsomal phosphatidylcholine and phosphatidylethanolamine in guinea-pigs. "( Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation.
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Vázquez, M, 1993
)
2.08
"Treatment with gemfibrozil, showed lower fat oxidation (32.3 +/- 13.9% vs 39.7 +/- 7.9%), and lower plasma concentrations of FFA and glycerol, but differences did not reach significance at the 0.05 level."( The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers.
Cramb, R; Head, A; Jakeman, PM; Kendall, MJ; Maxwell, S, 1993
)
0.63
"Treatment with gemfibrozil 600 mg twice daily for 4 months decreased S-Mg by 0.02 mmol/L (P =.02), and treatment with simvastatin 10 mg daily for 4 months again decreased S-Mg by 0.02 mmol/L (P =.10; not significant [NS]) The changes in S-Mg during the 2 different treatment periods were closely correlated (r = 0.66, P <.001)."( Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.
Haenni, A; Lithell, H; Ohrvall, M, 2001
)
0.65
"Treatment with gemfibrozil resulted in a reduction in serum triglyceride concentrations at all time points for at least 5 h after the meal (P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)"( Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins.
Arrol, S; Bhatnagar, D; Durrington, PN; Mackness, MI; Prais, H; Winocour, PH, 1992
)
0.88
"Treatment with gemfibrozil reduces the probability of AMI and sudden cardiac death events by 34%, as demonstrated in the HHS."( Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy.
Fifer, SK; Sarma, S, 1990
)
2.06

Toxicity

Pravastatin and gemfibrozil therapy is safe and efficacious in patients with mixed hyperlipidemia. Adverse reactions include alterations in liver function, cholestatic jaundice, and cholelithiasis.

ExcerptReferenceRelevance
" Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention."( Adverse effects of the treatment for hyperlipidemia.
Malinow, MR, 1986
)
0.27
"Close monitoring of selected, potentially adverse events amongst treated subjects after a placebo-controlled trial and comparing occurrences to those in various untreated groups."( The Helsinki Heart Study: an 8.5-year safety and mortality follow-up.
Frick, MH; Hakulinen, T; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Teppo, L, 1994
)
0.29
" Each patient was followed up at Out-patient Clinic regularly for diet interview, compliance and possible adverse events."( Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Chen, JW; Jen, SL; Lee, WL; Wang, SP, 1997
)
0.57
" There was no obvious adverse event noted during each treatment period with either drug."( Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Chen, JW; Jen, SL; Lee, WL; Wang, SP, 1997
)
0.57
" Physical and laboratory investigations for adverse effects were performed every month for the first 3 months and every 3 months thereafter."( Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA, 1997
)
0.3
"Pravastatin and gemfibrozil therapy is safe and efficacious in patients with mixed hyperlipidemia."( Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Iliadis, EA; Rosenson, RS, 1999
)
0.93
" Gemfibrozil treatment was also withdrawn significantly more frequently due to a possible adverse reaction compared with the other two drugs."( A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999
)
1.45
"In normal clinical practice in New Zealand gemfibrozil appears less effective and more frequently causes adverse effects leading to withdrawal of treatment than either bezafibrate or simvastatin."( A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999
)
0.8
" These results suggest that lovastatin and gemfibrozil are both safe and efficacious in transplant patients."( A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients.
Behrens, MT; Hanes, DS; Hooper, FL; Nicholson, PG; Raval, DD; Weir, MR,
)
0.63
" Adverse events occur more often with the statins that are metabolized via the CYP enzyme system and its 3A4, 2C9 or 2C19 paths."( Lipid-lowering drugs: are adverse effects predictable and reversible?
Muscari, A; Puddu, GM; Puddu, P, 2002
)
0.31
" Patients with concurrent prescriptions were surveyed for current use, awareness of withdrawal/warnings, adverse effects and creatine phosphokinase (CK) results."( High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic.
Bult, J; Keehr, LM; Sai, TT; Schiff, GD, 2002
)
0.31
"Statin monotherapy is generally well tolerated, with a low frequency of adverse events."( Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Bellosta, S; Corsini, A; Paoletti, R, 2004
)
0.32
"An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis."( Risk of adverse events with fibrates.
Alsheikh-Ali, AA; Karas, RH; Kuvin, JT, 2004
)
0.57
" So, the toxicogenomics through this technology may be very powerful for understanding the effect of unknown toxic mechanisms in biological system."( Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray.
Hwang, JW; Hwang, SY; Jeon, KS; Jung, JW; Kang, JS; Kang, KS; Kim, YS; Lee, GJ; Lee, WS; Lee, YS; Li, P; Oh, MJ; Park, JE; Park, JS; Song, BS; Um, CH; Yeo, CD; Youn, JP, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" We reviewed gemfibrozil- and fenofibrate-associated adverse event reports (AERs) submitted to the US Food and Drug Administration over a 5-year period."( Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Alsheikh-Ali, AA; Holoshitz, N; Karas, RH, 2008
)
1.04
" The risk of adverse effects is increased with their concomitant use."( [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Anić, B; Bosnić, D; Cikes, N; Huić, M; Markeljević, J; Mayer, M; Pazanin, L; Sentić, M,
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Overall, DCF was the most cytotoxic drug for zebra mussel cells, followed by GEM, CBZ, while ATL has not a noteworthy toxic potential."( Cytotoxicity assessment of four pharmaceutical compounds on the zebra mussel (Dreissena polymorpha) haemocytes, gill and digestive gland primary cell cultures.
Binelli, A; Parolini, M; Provini, A; Quinn, B, 2011
)
0.37
" Among the adverse reactions observed with gemfibrozil are alterations in liver function, cholestatic jaundice, and cholelithiasis."( Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity.
Brocker, C; Fang, ZZ; Gonzalez, FJ; Krausz, KW; Liu, A; Qu, A, 2014
)
2.11
" Clearly, longer acyl glucuronide half-lives were observed for safe drugs compared to drugs that can cause IDT."( Toxicity of Carboxylic Acid-Containing Drugs: The Role of Acyl Migration and CoA Conjugation Investigated.
Aatsinki, SM; Hokkanen, J; Lassila, T; Mattila, S; Tolonen, A; Turpeinen, M, 2015
)
0.42
" Gemfibrozil has shown efficacy in an animal model of NCL known as CLN2 (late infantile classic juvenile) and has been shown to be safe for lowering lipids in children."( Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.
Kim, K; Kleinman, HK; Lee, HJ; Pahan, K, 2017
)
1.65
"Cardiotoxicity is an adverse effect of the anticancer drug doxorubicin (DOX)."( Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats.
Aminzadeh, A; Fatemi, I; Goudarzi, M; Haybar, H; Kalantar, M; Khodayar, MJ; Mehrzadi, S, 2019
)
0.92
"Nephrotoxicity is a significant side effect of doxorubicin (DXN) treatment."( Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation.
Fatemi, I; Goudarzi, M; Hosseinzadeh, A; Karimi, MA; Khalili, HR; Khodayar, MJ; Mehrzadi, S, 2020
)
2

Pharmacokinetics

This LC/MS method yielded a quick, simple and reliable protocol for determining gemfibrozil concentrations in plasma. Clinical DDIs of montelukast were evaluated using physiologically based pharmacokinetic modeling.

ExcerptReferenceRelevance
"the half-life of gemfibrozil is independent of renal function for both single- and multiple-dose regimens."( The effect of renal function on the pharmacokinetics of gemfibrozil.
Cutler, RE; Evans, JR; Forland, SC, 1987
)
0.86
" Combinations of fibrates and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are effective, but because of safety concerns related to myopathy and rhabdomyolysis, it is important to consider the possibility of pharmacokinetic interactions when such combinations are used."( Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Hendricks, L; Khouri, HE; Latchinian, L; Munoz, CE; Spence, JD, 1995
)
0.54
"Comparative pharmacokinetic study was performed in 19 healthy male volunteers in a single-dose, randomized, two way cross-over trial on two preparations of gemfibrozil (Innogem and Lopid capsules) each of them containing 300 mg active ingredient."( [Bioanalysis of gemfibrozil. Comparative human pharmacokinetics of 300 mg of gemfibrozil-containing Innogem and Lopid capsules].
Benkóné Márkus, S; Csörgó, M; Drabant, S; Grézal, G; Klebovich, I; Urmös, I, 1996
)
0.84
"A comparative pharmacokinetic study has been performed in 19 healthy male volunteers in a single-dose, randomized, two way cross-over design with two preparations of gemfibrozil (CAS 25812-30-0) capsules each of them containing 300 mg active ingredient."( Pharmacokinetic and bioequivalence study of two gemfibrozil preparations.
Benkö, S; Csörgö, M; Drabant, S; Grézal, G; Klebovich, I; Urmös, I, 1997
)
0.75
" The results of pharmacokinetic studies suggest that the compound LM-1554 is poorly absorbed from the gastrointestinal tract after the oral administration in dogs and rabbits."( Mechanism of the antihyperlipaemic activity and pharmacokinetics of 2-chloromethyl-5,6,7,8-tetrahydrobenzo(b)thieno[2,3-d]pyrimidin-4(3H)-o ne.
Gandhi, TR; Goyal, RK; Jain, KS; Rathod, IS; Shishoo, CJ, 1997
)
0.3
" All members of this class are primarily excreted via the kidneys and display some increase in plasma half-life in individuals with severe renal impairment."( Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Miller, DB; Spence, JD, 1998
)
0.3
"05), but there was no difference in the half-life between the phases."( Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
Backman, JT; Kyrklund, C; Neuvonen, M; Neuvonen, PJ, 2003
)
1.76
"Coadministration of statins and gemfibrozil is associated with an increased risk for myopathy, which may be due in part to a pharmacokinetic interaction."( The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Birmingham, BK; Brown, CD; Lasseter, KC; Martin, PD; Mitchell, PD; Raza, A; Schneck, DW; Wang, Y; Windass, AS; Zalikowski, JA, 2004
)
0.97
" This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions."( Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Bellosta, S; Corsini, A; Paoletti, R, 2004
)
0.32
"To characterize the pharmacokinetics of simvastatin (SV) and simvastatin acid (SVA), a lactone-acid pair known to undergo reversible metabolism, and to better understand mechanisms underlying pharmacokinetic interactions observed between SV and gemfibrozil."( Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil.
Brunner, J; Lin, JH; Michel, K; Mu, L; Prueksaritanont, T; Qiu, Y; Richards, KM, 2005
)
0.73
" Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates."( Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson, MH, 2006
)
0.56
" The application of the assay in an oral pharmacokinetic study in rats co-administered with RST and GFZ is described."( Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study.
Kumar, TR; Mullangi, R; Shitut, NR; Srinivas, NR; Vinu, MC; Vittal, S, 2006
)
0.59
"The evaluation of drug disposition properties of chemical entities in drug discovery research typically involves the conduct of pharmacokinetic studies in rodents that requires blood sampling over several time points, preferably without disrupting the physiological status of the animals."( Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs.
Bina, H; Chiang, A; Ebbert, L; Huang, NH; Hui, YH; Kern, T; Maples, C; Patel, N; Pritt, M,
)
0.13
" Multivariable data analysis was employed to explore the relationship between pharmacokinetic parameters and myotoxicity markers."( Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties.
Dai, R; Gonzalez, FJ; Liu, A; Sun, H; Wei, X; Xie, S, 2009
)
0.71
" The absence of a significant pharmacokinetic interaction between fenofibrate and atorvastatin is consistent with recent results showing no difference in safety profile between atorvastatin as monotherapy or in combination with fenofibric acid."( Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR, 2011
)
0.77
" Furthermore, there were no statistically significant differences in the peak plasma concentration, time of peak concentration, or elimination half-life of zafirlukast between the phases."( The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Backman, JT; Karonen, T; Neuvonen, PJ, 2011
)
0.69
" This LC/MS method yielded a quick, simple and reliable protocol for determining gemfibrozil concentrations in plasma and is applicable to clinical pharmacokinetic studies."( Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study.
Aquilante, CL; Bushman, LR; Hammond, KP; Kadam, RS; Rower, JE, 2010
)
0.83
" The interindividual differences in the pharmacokinetic parameters of sitagliptin were found to be within acceptable limits (coefficient of variation <20%)."( Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.
B, S; Dubala, A; K P, A; K, E; Kucherlapati, VS; M, D; Meda, VS; P R, AV, 2012
)
0.64
" The method was successfully used to analyze rats plasma samples for application in pharmacokinetic studies."( Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats.
Cao, Q; Jin, L, 2012
)
0.78
" The complex pharmacokinetic and pharmacogenetic properties and the unfavourable short and long term risk profile of glibenclamide and glimepiride raise the question whether their use can be justified any longer."( CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.
Beil, W; Holstein, A; Kovacs, P, 2012
)
0.38
" S-warfarin AUC(0- ∞) decreased 37% and Cmax increased 18% with dabrafenib."( Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Aktan, G; Arkenau, HT; Blackman, SC; Botbyl, J; Carson, SW; Gordon, MS; Grossmann, KF; Infante, JR; Kendra, K; LoRusso, PM; Middleton, MR; Ouellet, D; Pant, S; Patel, M; Richards-Peterson, LE; Sharma, S; Suttle, AB, 2015
)
0.42
"The present study aimed to examine the potential pharmacokinetic drug interaction between valsartan and gemfibrozil."( Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats.
Han, HK; Kim, BJ; Mo, L; Yang, SJ, 2016
)
0.87
"This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling."( Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
Chen, Y; Lin, J; Mao, J; Peters, S; Shebley, M; Templeton, IE; Varma, MV; Yu, H, 2016
)
0.43
" Clinical DDIs of montelukast were evaluated using physiologically based pharmacokinetic modeling; and simulation of the interactions with gemfibrozil-CYP2C8 and OATP1B1/1B3 inhibitor, clarithromycin-CYP3A and OATP1B1/1B3 inhibitor, and itraconazole-CYP3A inhibitor, implicated OATPs-CYP2C8-CYP2C8 interplay as the primary determinant of montelukast pharmacokinetics."( Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.
Bi, Y; El-Kattan, AF; Eng, H; Kalgutkar, AS; Kimoto, E; Lin, J; Rodrigues, AD; Scialis, R; Tremaine, LM; Varma, MV, 2017
)
0.66
" This report describes the development of a physiologically based pharmacokinetic (PBPK) model of rosuvastatin for prediction of pharmacokinetic (PK) DDIs."( Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Leil, T; Wang, Q; Zheng, M, 2017
)
0.46
" The present study evaluated the possible pharmacokinetic interactions of selexipag with gemfibrozil, a strong CYP2C8 inhibitor, and rifampicin, an inducer of CYP2C8."( Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Boehler, M; Bruderer, S; Dingemanse, J; Halabi, A; Petersen-Sylla, M; Remeňová, T, 2017
)
1.08
" The purpose of this study was to describe the transporter-/enzyme-mediated drug-drug interactions (DDIs) of CER with CsA or GEM based on unified physiologically based pharmacokinetic (PBPK) models and to investigate whether the DDIs can be quantitatively analyzed by a bottom-up approach."( Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
Kim, SJ; Sugiyama, Y; Toshimoto, K; Yao, Y; Yoshikado, T, 2018
)
0.48
"We previously verified a physiologically based pharmacokinetic (PBPK) model for mirabegron in healthy subjects using the Simcyp Simulator by incorporating data on the inhibitory effect on cytochrome P450 (CYP) 2D6 and a multi-elimination pathway mediated by CYP3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7 and butyrylcholinesterase (BChE)."( Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K, 2019
)
0.51
" The method was applied in a pharmacokinetic study following administration of multiple doses of 600 mg GFZ every 12 h in healthy volunteers (n = 15)."( UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers.
Cestari, RN; de Oliveira, RDR; Lanchote, VL; Rocha, A, 2019
)
0.83

Compound-Compound Interactions

Gemfibrozil, poor anti-hyperglycemic combined with metformin, evaluated for MMP-9, IL-10 and adiponectin beyond glycemic control. Despite these concerns, there are situations in which the use of gemfibros in combination with a statin may be necessary.

ExcerptReferenceRelevance
"Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study."( The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Eichinger, M; Feussner, G; Ziegler, R, 1992
)
0.7
" However, when colestipol was given with gemfibrozil, there was a decrease in AUC (43."( Apparent reduced absorption of gemfibrozil when given with colestipol.
Cutler, RE; Feng, Y; Forland, SC, 1990
)
0.83
"Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance."( Drug interactions with fibric acids.
Dujovne, CA; Lozada, A, 1994
)
0.29
" For example, HMG-CoA reductase inhibitors may interact with macrolides, azalides, azole antifungals and cyclosporin."( Drug interactions of lipid-altering drugs.
Bays, HE; Dujovne, CA, 1998
)
0.3
" Although statin therapy remains the mainstay of treatment for hyperlipidemia in the elderly, other therapies, including exercise training, plant stanols and sterols, soluble fiber, and drug combinations (especially ezetimibe, niacin, and/or fibrates alone or combined with statins) are also effective and important lipid therapies for the elderly population."( Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations.
Lavie, CJ,
)
0.13
" However, considering the possibly concentrated high unbound concentrations of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metabolism of CER appears to be the main mechanism for the clinically relevant drug-drug interaction."( Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction
Hirano, M; Sato, H; Shitara, Y; Sugiyama, Y, 2004
)
1.77
" Although the National Cholesterol Education Programme Adult Treatment Panel III guidelines recommend the use of fibrates in combination with statins in patients at very high risk of CHD (e."( Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson, MH, 2006
)
0.33
"The aim of this report was to describe a potential drug-drug interaction between IFN alfa-2b and gemfibrozil in a patient with malignant melanoma."( Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Jakowatz, JG; Taheri, R; Wong, SF, 2005
)
0.79
"In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment)."( Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Jakowatz, JG; Taheri, R; Wong, SF, 2005
)
0.79
" A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia."( Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Jakowatz, JG; Taheri, R; Wong, SF, 2005
)
0.81
"Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic elimination of many drugs and potentially associated drug-drug interactions."( Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Brun, ME; Funk, C; Noé, J; Portmann, R, 2007
)
0.59
"To assess the consequences of multiple inhibitors and differential inhibition mechanisms on the prediction of 12 gemfibrozil drug-drug interactions (DDIs)."( Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.
Galetin, A; Hinton, LK; Houston, JB, 2008
)
0.76
"In vitro investigation of pharmacokinetic drug-drug interactions (DDIs) has officially been part of the regulatory pathway for new drugs in the USA since the publication of an FDA guidance on the subject in 1997."( The nasty surprise of a complex drug-drug interaction.
Bode, C, 2010
)
0.36
"To further explore the mechanism underlying the interaction between repaglinide and gemfibrozil, alone or in combination with itraconazole."( Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism.
Chen, W; Gan, J; Gao, L; Hong, Y; Humphreys, WG; Li, W; Rodrigues, AD; Shen, H; Tang, Y; Tian, Y; Zhang, H; Zhang, Y, 2010
)
0.96
"To support drug development, the drug-drug interaction potential (DDI) of an investigational drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against simvastatin acid, atorvastatin, pravastatin, pitavastatin, fluvastatin, rosuvastatin and estrone 3-sulfate."( Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.
Butters, CJ; Elsby, R; Sharma, P; Smith, V; Surry, D, 2012
)
0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"The objective of this study was to determine the extent to which the CYP2C8*3 allele influences pharmacokinetic variability in the drug-drug interaction between gemfibrozil (CYP2C8 inhibitor) and pioglitazone (CYP2C8 substrate)."( Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
Aquilante, CL; Bourne, DW; Bushman, LR; Daily, EB; Hammond, KP; Hopley, CW; Kadam, RS; Kanack, AT; Kompella, UB; Kosmiski, LA; Le, M; Predhomme, JA; Rower, JE; Sidhom, MS, 2013
)
0.82
"CYP2C8*3 is associated with decreased pioglitazone plasma exposure in vivo and significantly influences the pharmacokinetic magnitude of the gemfibrozil-pioglitazone drug-drug interaction."( Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
Aquilante, CL; Bourne, DW; Bushman, LR; Daily, EB; Hammond, KP; Hopley, CW; Kadam, RS; Kanack, AT; Kompella, UB; Kosmiski, LA; Le, M; Predhomme, JA; Rower, JE; Sidhom, MS, 2013
)
0.82
"To develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI) of pravastatin, using the in vitro transport parameters."( Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Bergman, A; Feng, B; Goosen, TC; Lai, Y; Litchfield, J; Varma, MV, 2012
)
0.38
" Gemfibrozil, poor anti-hyperglycemic combined with metformin, evaluated for MMP-9, IL-10 and adiponectin beyond glycemic control."( Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.
Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP, 2013
)
2.74
"911, P = ns), hence combined with metformin showed synergistic activity, reduced the MMP-9 levels (-16."( Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.
Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP, 2013
)
1.83
"Quantitative prediction of complex drug-drug interactions (DDIs) is challenging."( Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
El-Kattan, AF; Goosen, TC; Kimoto, E; Kumar, V; Lai, Y; Varma, MV, 2013
)
0.39
"The risk assessment of organic anion transporting polypeptide (OATP) 1B1-mediated drug-drug interactions (DDIs) is an indispensable part of drug development."( Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
Izumi, S; Komori, T; Kusuhara, H; Maeda, K; Nozaki, Y; Sugiyama, Y; Takenaka, O, 2015
)
0.42
" However, gemfibrozil drug-drug interactions (DDIs) are complex; its major circulating metabolite, gemfibrozil 1-O-β-glucuronide (Gem-Glu), exhibits time-dependent inhibition of CYP2C8, and both parent and metabolite also behave as moderate inhibitors of organic anion transporting polypeptide 1B1 (OATP1B1) in vitro."( Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
Bi, YA; Kimoto, E; Lin, J; Rodrigues, AD; Varma, MV, 2015
)
1.1
"While co-administered gemfibrozil can increase the area under the concentration/time curve (AUC) of pioglitazone more than 3-fold, the underlying mechanism of the drug-drug interaction between gemfibrozil and pioglitazone has not been fully understood."( Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8.
Fujiwara, R; Itoh, T; Sakamoto, M; Takagi, M, 2015
)
0.96
" However, despite these concerns, there are situations in which the use of gemfibrozil in combination with a statin may be necessary."( Gemfibrozil in Combination with Statins-Is It Really Contraindicated?
Morris, PB; Saseen, JJ; Wiggins, BS, 2016
)
2.11
"This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling."( Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
Chen, Y; Lin, J; Mao, J; Peters, S; Shebley, M; Templeton, IE; Varma, MV; Yu, H, 2016
)
0.43
" We evaluated the quantitative role of hepatic uptake transport in its pharmacokinetics and drug-drug interactions (DDIs)."( Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.
Bi, Y; El-Kattan, AF; Eng, H; Kalgutkar, AS; Kimoto, E; Lin, J; Rodrigues, AD; Scialis, R; Tremaine, LM; Varma, MV, 2017
)
0.46
"Rosuvastatin is a frequently used probe in transporter-mediated drug-drug interaction (DDI) studies."( Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Leil, T; Wang, Q; Zheng, M, 2017
)
0.46
"Quantitative analysis of transporter- and enzyme-mediated complex drug-drug interactions (DDIs) is challenging."( Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
Kim, SJ; Sugiyama, Y; Toshimoto, K; Yao, Y; Yoshikado, T, 2017
)
0.67
" We investigate, as an example, the impact of CYP3A4-CYP2C8 intercorrelation on the predicted interindividual variabilities of clearance and drug-drug interactions (DDIs) for repaglinide using physiologically based pharmacokinetic (PBPK) modelling."( Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
Achour, B; Backman, JT; Darwich, AS; Doki, K; Rostami-Hodjegan, A; Tornio, A, 2018
)
0.48
" The purpose of this study was to describe the transporter-/enzyme-mediated drug-drug interactions (DDIs) of CER with CsA or GEM based on unified physiologically based pharmacokinetic (PBPK) models and to investigate whether the DDIs can be quantitatively analyzed by a bottom-up approach."( Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
Kim, SJ; Sugiyama, Y; Toshimoto, K; Yao, Y; Yoshikado, T, 2018
)
0.48
" The genotoxicity of AuNPs, alone or combined with the human pharmaceutical gemfibrozil (GEM), an environmental contaminant frequently detected in aquatic systems, including in marine ecosystems, was examined using gilthead seabream erythrocytes as a model system."( Genotoxicity of gold nanoparticles in the gilthead seabream (Sparus aurata) after single exposure and combined with the pharmaceutical gemfibrozil.
Almeida, A; Barreto, A; Delerue-Matos, C; Hylland, K; Loureiro, S; Luis, LG; Oliveira, M; Paíga, P; Pinto, E; Santos, LHMLM; Soares, AMVM; Trindade, T, 2019
)
0.95
" Understanding potential drug-drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies."( Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L, 2022
)
0.72

Bioavailability

Oral bioavailability of ezetimibe coadministered with gemfibrozil relative to each drug administered alone was evaluated with an analysis-of-variance model. Data suggest a reduction of gemfipol bioavailability when colestipol is administered concomitantly. The interaction may not have any clinical significance as sitagliptin has a wide therapeutic index.

ExcerptReferenceRelevance
" The data suggest a reduction of gemfibrozil bioavailability when colestipol is administered concomitantly."( Apparent reduced absorption of gemfibrozil when given with colestipol.
Cutler, RE; Feng, Y; Forland, SC, 1990
)
0.85
" The relative bioavailability of Innogem with respect to Lopid 300 mg capsule for AUC0-infinity was 104."( [Bioanalysis of gemfibrozil. Comparative human pharmacokinetics of 300 mg of gemfibrozil-containing Innogem and Lopid capsules].
Benkóné Márkus, S; Csörgó, M; Drabant, S; Grézal, G; Klebovich, I; Urmös, I, 1996
)
0.64
" The relative bioavailability of the test preparation with respect to the reference preparation in terms of the AUC0-oc was 104."( Pharmacokinetic and bioequivalence study of two gemfibrozil preparations.
Benkö, S; Csörgö, M; Drabant, S; Grézal, G; Klebovich, I; Urmös, I, 1997
)
0.55
" The results of pharmacokinetic studies suggest that the compound LM-1554 is poorly absorbed from the gastrointestinal tract after the oral administration in dogs and rabbits."( Mechanism of the antihyperlipaemic activity and pharmacokinetics of 2-chloromethyl-5,6,7,8-tetrahydrobenzo(b)thieno[2,3-d]pyrimidin-4(3H)-o ne.
Gandhi, TR; Goyal, RK; Jain, KS; Rathod, IS; Shishoo, CJ, 1997
)
0.3
" As a class, these drugs are generally well absorbed from the gastrointestinal tract (immediate-acting fenofibrate being the exception) and display a high degree of binding to albumin."( Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Miller, DB; Spence, JD, 1998
)
0.3
" These differences may be due to interactions between genetic and environmental factors that effect drug bioavailability or the capacity of the lipid-regulating enzyme and receptor targets to be affected."( Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia.
Ballesta, AM; Casals, E; Ojuel, J; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Zambón, D, 1998
)
0.52
" Because of low bioavailability of these drugs for keratinocytes, the incidence is extremely low clinically."( Effects of gemfibrozil on in vitro cultured normal human skin explants.
de Angelis, F; Lo Schiavo, A; Ruocco, V; Russo, A; Wolf, R, 1999
)
0.69
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation."( Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating, GM; Ormrod, D, 2002
)
0.31
" The oral bioavailability of ezetimibe coadministered with gemfibrozil relative to each drug administered alone was evaluated with an analysis-of-variance model."( Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P, 2004
)
0.77
" Ezetimibe did not alter the bioavailability (based on AUC) of gemfibrozil."( Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P, 2004
)
0.77
" Cannula-bleeding, especially coupled with automated blood-collection techniques, has become the most efficient way for pharmaceutical industry to perform rat bioavailability studies."( Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs.
Bina, H; Chiang, A; Ebbert, L; Huang, NH; Hui, YH; Kern, T; Maples, C; Patel, N; Pritt, M,
)
0.13
" This method was successfully used to study the pharmacokinetics and bioavailability of CA in rats."( High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study.
Jiang, Y; Li, X; Lu, W; Tu, P; Wang, L; Wu, L; Yan, H; Yu, C; Zhang, K, 2009
)
0.35
" Previous results suggest that vascular dysfunction in OZR is associated with chronic reduction in vascular nitric-oxide (NO) bioavailability and chronic inflammation, both frequently associated with hypercholesterolemia."( Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009
)
0.35
"While the positive impact of chronic statin treatment on vascular outcomes in the metabolic syndrome are independent of changes to total cholesterol, and are more strongly associated with improvements to vascular NO bioavailability and attenuated inflammation, these results provide both a spatial and temporal framework for targeted investigation into mechanistic determinants of vasculopathy in the metabolic syndrome."( Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009
)
0.35
"Although the bioavailability of sitagliptin was increased by 54% when co-administered with gemfibrozil, this interaction may not have any clinical significance as sitagliptin has a wide therapeutic index."( Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.
B, S; Dubala, A; K P, A; K, E; Kucherlapati, VS; M, D; Meda, VS; P R, AV, 2012
)
0.87
" Consequently, the bioavailability of mitiglinide in the presence of gemfibrozil was significantly enhanced compared to that in oral control group (only mitiglinide)."( Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats.
Cao, Q; Jin, L, 2012
)
1.02
" Consequently, the oral bioavailability of valsartan was significantly higher (p < 0."( Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats.
Han, HK; Kim, BJ; Mo, L; Yang, SJ, 2016
)
0.65
" In vivo and in vitro studies were performed to assess absolute bioavailability of finerenone, the effect of metabolic enzyme inhibitors on the pharmacokinetics of finerenone and its metabolites, the quantitative contribution of the involved enzymes cytochrome P450 (CYP) 3A4 and CYP2C8 and the relevance of gut wall versus liver metabolism."( Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo.
Engelen, A; Gerisch, M; Heinig, R; Loewen, S; Nagelschmitz, J, 2018
)
0.48
" Absolute bioavailability was assessed in volunteers receiving finerenone orally and by intravenous infusion (n = 15) and the effects of erythromycin (n = 15), verapamil (n = 13) and gemfibrozil (n = 16) on finerenone pharmacokinetics were investigated."( Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo.
Engelen, A; Gerisch, M; Heinig, R; Loewen, S; Nagelschmitz, J, 2018
)
0.67
" Often, the salt with the best solubility is not chosen due to other factors such as stability, solubility, dissolution and bioavailability that are taken into consideration during the preformulation stage."( Direct imaging of the dissolution of salt forms of a carboxylic acid drug.
Adebisi, A; Alshafiee, M; Asare-Addo, K; Bondi, A; Conway, BR; Evans, W; Mawla, N; Taheri, S; Timmins, P; Totea, AM; Walton, K; Ward, A, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Gemfibrozil was given in a constant dosage of 600 mg twice daily in both strata. The effects of cholestyramine rapidly disappeared when it was withdrawn from the diet, while the effects of gemfibrazil persisted after dosage was stopped. A strong CYP2C8 inhibitory effect persisted even after gemfibia and gemfiba concentrations had decreased to less than 1%.

ExcerptRelevanceReference
" This retrospective data analysis suggests that the combination of gemfibrozil and lovastatin may be safe in patients with normal renal function when the dosage of lovastatin is limited and when CK and ALT levels are monitored carefully."( A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin.
McIntyre, TH; Shapiro, ML; Whitney, EJ; Wirebaugh, SR, 1992
)
0.74
" Further long term studies are necessary to determine its optimal dosage and its long term safety in Indian subjects."( Gemfibrozil in hyperlipidaemia: an open, single blind trial.
Joshi, VR; Nihalani, KD; Salgaonkar, DS; Sharma, SS; Turakhia, DP; Varthakavi, PK, 1990
)
1.72
" Gemfibrozil was given in a constant dosage of 600 mg twice daily in both strata."( Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.
Bocanegra, TS; Cook, T; Tikkanen, MJ; Walker, JF, 1989
)
1.46
" The patients were treated with gemfibrozil on a constant dosage (range 900-1200 mg/day) during the entire trial."( Guar gum and gemfibrozil--an effective combination in the treatment of hypercholesterolaemia.
Aro, A; Manninen, V; Silvasti, M; Tuomilehto, J; Uusitupa, M, 1989
)
0.93
"2-fold) but not clofibrate or bezafibrate when dosed PO at 50 mg/kg for 2 weeks in cholesterol-fed rats."( Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Krause, BR; Newton, RS, 1986
)
1.71
" Most of these drugs have side effects which, in the elderly, may necessitate lower dosing than usual."( Treating hyperlipidemia, Part III: Drug therapy.
Brown, WV; Karmally, W; Smith, DA, 1987
)
0.27
" Reduced dosage was easily detected in the marker results."( Minimal doses of digoxin: a new marker for compliance to medication.
Heinonen, OP; Javela, K; Mäenpää, H; Mälkönen, M; Manninen, V; Pikkarainen, J, 1987
)
0.27
" In the poor compliance group, defined with the use of the digoxin marker, there was 39% of subjects who returned less than 5% of their capsule dosage or reported a deviation less than 5%."( Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial.
Heinonen, OP; Mäenpää, H; Manninen, V, 1987
)
0.27
" Group 1 received the standard gemfibrozil dosage of two 300-mg capsules 2 times a day, for a total daily dosage equal to 1,200 mg."( A comparison of different formulations and dosage administrations of gemfibrozil.
Koskinen, P; Kovanen, PT; Manninen, V, 1986
)
0.79
" Dosing schedules do not require alteration for renal insufficiency."( The effect of renal function on the pharmacokinetics of gemfibrozil.
Cutler, RE; Evans, JR; Forland, SC, 1987
)
0.52
" The effects of cholestyramine rapidly disappeared when it was withdrawn from the diet, while the effects of gemfibrozil persisted after dosage was stopped."( Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
Maxwell, RE; Nawrocki, JW; Uhlendorf, PD, 1983
)
0.77
"In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia."( The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Nye, ER; Sutherland, WH; Temple, Wa, 1980
)
0.78
" The rate of gemfibrozil-protein adduct accumulation seemed greatest in liver, but was similar in kidney and plasma, with approximately 2x, 16x, and 30x accumulation, respectively, over the dosing interval."( Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats.
Foster, DJ; Sallustio, BC, 1995
)
1.02
" No untoward effects of gemfibrozil on acitretin dose-response and clinical side-effects were noted."( Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study.
Lindholm, A; Olsson, AG; Vahlquist, A; Vahlquist, C, 1995
)
0.99
" Chow-fed rats were orally gavaged daily with a dosing vehicle alone or with 100 mg/kg of each of the fibrates for 1 week and in addition with gemfibrozil for 2 weeks."( Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME, 1995
)
0.49
" A metaanalysis of ten trials has shown a 25% decrease in vascular events in the long-term, irrespective of age, gender, blood pressure blood glucose level, and dosage whether low (75 to 160 mg) or moderate (160 to 325 mg/day)."( [Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Aumont, MC; Seknadji, P, 1996
)
0.29
" After 12 weeks of induction of diabetes, the control and diabetic rats were orally gavaged daily with a dosing vehicle alone or with 100 mg/kg of gemfibrozil for 2 weeks."( Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats.
Akin, B; Aktan, F; Karasu, C; Ozansoy, G, 2001
)
0.9
" Combination treatment with the same dosage of gemfibrozil and orlistat at 120 mg orally three times a day reduced triglyceride levels to 279 mg/dL and 244 mg/dL on two separate occasions."( Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia.
Ferenczi, A; Poretsky, L; Ronen, L; Tolentino, MC,
)
0.74
" Patients receiving concomitant statin therapy before crossover continued the statin at the same dosage after crossover."( Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.
Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002
)
0.68
" Dosage reduction is therefore compulsory in patients with compromised renal function, no matter which type of renal replacement therapy they receive."( Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy.
Chang, CT; Huang, CC; Wu, MS; Yen, TH, 2003
)
0.62
"Crude GG was extracted from the urine of volunteers dosed with 600 mg of gemfibrozil, and this material was then purified by reversed-phase high-performance liquid chromatography to yield a white solid."( Self-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution.
Charman, WN; Prankerd, RJ; Scanlon, MJ; Shackleford, DM, 2003
)
0.87
" If the combination is considered necessary, repaglinide dosage should be greatly reduced and blood glucose concentrations carefully monitored."( Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M, 2003
)
0.71
" On the fourth morning of each dosing period, a single oral dose of rosuvastatin, 80 mg, was coadministered."( The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Birmingham, BK; Brown, CD; Lasseter, KC; Martin, PD; Mitchell, PD; Raza, A; Schneck, DW; Wang, Y; Windass, AS; Zalikowski, JA, 2004
)
0.68
" It is advisable to increase the dosage of atorvastatin and preferable to administer it in the evening to guarantee adequate concentrations during the nighttime rapid cholesterol synthesis when rifampin or other potent inducers of cytochrome P450 3A4 are coadministered."( Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman, JT; Luurila, H; Neuvonen, M; Neuvonen, PJ, 2005
)
0.61
" Careful blood glucose monitoring and dosage adjustments are suggested during coadministration of pioglitazone and gemfibrozil."( Effect of gemfibrozil on the pharmacokinetics of pioglitazone.
Deng, LJ; Li, HD; Wang, F, 2005
)
0.94
" Solid dosage forms (hydroxypropylmethyl cellulose /HPMC/ capsules and tablets) were prepared from the selected products on the basis of their dissolution profile and the in vitro membrane diffusion results."( [Preparation and investigation of gemfibrozil + dimethyl-beta-cyclodextrin products and solid dosage forms].
Aigner, Z; Eros, I; Hassan, BH; Hódi, K; Kása, P, 2005
)
0.61
" As for other statins, only limited data was available for the relationship between the dosage and the rate of myopathy."( [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M, 2005
)
0.33
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" We studied the effect of dosing interval on the extent of the gemfibrozil-repaglinide interaction."( The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Backman, JT; Kalliokoski, A; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A, 2008
)
0.95
" An unusual dose-response pattern was observed in that at 6 mg/day CP-778,875 only increased HDL cholesterol by 3% and decreased HDL(2) cholesterol by 24%."( Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG, 2008
)
0.35
" Six Cynomolgus monkeys were dosed with gemfibrozil twice daily at 600 mg/kg/day for the first two periods (P1 and P2, 8 days and 9 days respectively) and 300 mg/kg/day for the third period (P3, 14 days)."( Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties.
Dai, R; Gonzalez, FJ; Liu, A; Sun, H; Wei, X; Xie, S, 2009
)
0.97
" Regardless of the fibric acid derivative chosen, an empiric dosage reduction of 20% and close INR monitoring are warranted in patients receiving warfarin."( Interaction between gemfibrozil and warfarin: case report and review of the literature.
Dixon, DL; Williams, VG, 2009
)
0.68
" Thus, a strong CYP2C8 inhibitory effect persisted even after gemfibrozil and gemfibrozil 1-O-beta-glucuronide concentrations had decreased to less than 1% of their maximum (24-h dosing interval)."( CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman, JT; Honkalammi, J; Kurkinen, KJ; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A, 2009
)
0.85
"The hepatobiliary transport and local disposition of rosuvastatin in pig were investigated, along with the impact of concomitant dosing with two known multiple transport inhibitors; cyclosporine and gemfibrozil."( Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil.
Bergman, E; Bondesson, U; Fridblom, P; Hedeland, M; Knutson, L; Lennernäs, H; Lundahl, A, 2009
)
0.75
" This approach employs a common simple pharmacological model to describe the dose-response function."( A synergism model for PPARalpha and PXR agonist effects on HDL-cholesterol and apoA1.
Bachmann, KA; Batayneh, Z; White, DB, 2010
)
0.36
" After the rats were dosed with gemfibrozil by oral gavage, microsomes were prepared."( Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats.
Dai, R; Jiao, X; Liu, A; Ma, Q; Tang, Z; Yang, J; Zhao, W; Zhao, X, 2011
)
0.93
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"The dissolution properties of a drug and its release from the dosage form have a basic impact on its bioavailability."( Formulation of poorly water-soluble Gemfibrozil applying power ultrasound.
Aigner, Z; Ambrus, R; Naghipour Amirzadi, N; Szabó-Révész, P, 2012
)
0.65
" Patients were stratified according to statin and dosage to identify against-label combination use (e."( Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford, JC; Allen, RR; Nair, KV; Saseen, JJ, 2012
)
0.38
" Chemical-specific and mechanistic data support concordance of temporal and dose-response relationships for the key events associated with many PPARα activators including a phthalate ester plasticizer di(2-ethylhexyl) phthalate (DEHP) and the drug gemfibrozil."( Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study.
Corton, JC; Cunningham, ML; Hummer, BT; Klaunig, JE; Lau, C; Meek, B; Peters, JM; Popp, JA; Rhomberg, L; Seed, J, 2014
)
0.58
" In this study, wild-type and Ppara-null mice were dosed with a gemfibrozil-containing diet for 14 days."( Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity.
Brocker, C; Fang, ZZ; Gonzalez, FJ; Krausz, KW; Liu, A; Qu, A, 2014
)
2.08
"  Methotrexate, gemfibrozil and glipizide were used as test compounds and were dosed either orally or intravenously, followed by DBS collection and LC-MS/MS analysis to compare PK with various bleeding methods."( Evaluation and Optimization of Blood Micro-Sampling Methods: Serial Sampling in a Cross-Over Design from an Individual Mouse.
Barr, A; Hanes, J; Hui, YH; Kern, T; Masterson, N; Patel, NJ; Perkins, E; Ruterbories, K; Weller, J; Wickremsinhe, E,
)
0.48
"5%) for 14 days to establish a dose-response relationship for CYP induction."( Peroxisome Proliferator-Activated Receptor α Activation Suppresses Cytochrome P450 Induction Potential in Mice Treated with Gemfibrozil.
Dai, M; Gonzalez, FJ; Hua, H; Liu, A; Min, L; Shi, C; Song, D; Xu, G; Yang, J, 2017
)
0.66
" Chronic water borne exposures of adult zebrafish to 10 μg/L of GEM and CBZ were conducted and the dosing was confirmed by chemical analysis of water as 17."( Gemfibrozil and carbamazepine decrease steroid production in zebrafish testes (Danio rerio).
Fraz, S; Lee, AH; Wilson, JY, 2018
)
1.92
" Full dosage form (capsule) imaging showed an improvement over the GEM for all the salts with an increase in chain length of the counterion bringing about a decrease in dissolution which correlated with the obtained UV-imaging IDR data."( Direct imaging of the dissolution of salt forms of a carboxylic acid drug.
Adebisi, A; Alshafiee, M; Asare-Addo, K; Bondi, A; Conway, BR; Evans, W; Mawla, N; Taheri, S; Timmins, P; Totea, AM; Walton, K; Ward, A, 2018
)
0.48
" Understanding potential drug-drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies."( Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L, 2022
)
0.72
" Gemfibrozil glucuronide was formed in the liver microsomes of hUGT2 mice and was mainly excreted in the bile of hUGT2 mice after intravenous dosing of gemfibrozil."( Analysis of in vitro and in vivo metabolism of zidovudine and gemfibrozil in trans-chromosomic mouse line expressing human UGT2 enzymes.
Abe, S; Deguchi, T; Kajitani, N; Kazuki, K; Kazuki, Y; Kobayashi, K; Kurihara, A; Nakamura, K; Oshimura, M; Takehara, S, 2022
)
1.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (50)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency47.45700.007215.758889.3584AID1224835; AID588342
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
phosphopantetheinyl transferaseBacillus subtilisPotency51.45320.141337.9142100.0000AID1490
GLI family zinc finger 3Homo sapiens (human)Potency17.01820.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency44.48790.000221.22318,912.5098AID743035; AID743036; AID743063
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency34.65840.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency36.20920.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency54.94770.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency41.34520.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency69.93640.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency42.78620.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
aryl hydrocarbon receptorHomo sapiens (human)Potency48.90360.000723.06741,258.9301AID743085; AID743122
cytochrome P450 2C9 precursorHomo sapiens (human)Potency6.30960.00636.904339.8107AID883
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency65.10440.000323.4451159.6830AID743065
histone deacetylase 9 isoform 3Homo sapiens (human)Potency69.04470.037617.082361.1927AID1259364; AID1259388
importin subunit beta-1 isoform 1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency76.95880.000627.21521,122.0200AID651741
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.95260.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency0.56230.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency4.46680.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency79.43280.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency15.84890.251215.843239.8107AID504327
Interferon betaHomo sapiens (human)Potency27.54040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency6.30960.00638.235039.8107AID883
TAR DNA-binding protein 43Homo sapiens (human)Potency25.11891.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency21.33130.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Ki90.43000.01501.24876.9200AID407366; AID407369
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)4.10000.00081.88487.9000AID705607
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)7.07950.10472.71957.0795AID977603
CDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)IC50 (µMol)170.60000.73103.79949.0780AID1323834
CDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)Ki7.29100.03101.20547.2910AID1323835
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)45.76850.05002.37979.7000AID1218863; AID1218864; AID1218865; AID977600
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TransthyretinHomo sapiens (human)Kd0.10000.00301.348210.0000AID1239060
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)121.33330.00000.992210.0000AID1810339; AID299412; AID391553
Cannabinoid receptor 2Mus musculus (house mouse)EC50 (µMol)147.80000.00730.15460.7040AID391553
Guanylate cyclase soluble subunit alpha-1Homo sapiens (human)EC50 (µMol)624.00001.02001.02001.0200AID1770500
Guanylate cyclase soluble subunit beta-1Homo sapiens (human)EC50 (µMol)624.00001.02001.02001.0200AID1770500
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)114.35000.00061.607410.0000AID1810337; AID299410; AID391555; AID620228
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (230)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
blood circulationGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
regulation of blood pressureGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
positive regulation of nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
nitric oxide-cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
relaxation of vascular associated smooth muscleGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
retrograde trans-synaptic signaling by nitric oxide, modulating synaptic transmissionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
blood circulationGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
nitric oxide-cGMP-mediated signalingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cellular response to nitric oxideGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
trans-synaptic signaling by nitric oxide, modulating synaptic transmissionGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
regulation of autophagyCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
regulation of cellular respirationCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
protein maturation by [2Fe-2S] cluster transferCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (107)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
protein bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
signaling receptor activityGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
adenylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
protein bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
signaling receptor activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
protein-containing complex bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
metal ion bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cytidylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
Hsp90 protein bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
pyridoxal phosphate bindingCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
identical protein bindingCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
protein homodimerization activityCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
metal ion bindingCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
L-cysteine transaminase activityCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
2 iron, 2 sulfur cluster bindingCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (49)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
glutamatergic synapseGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cytosolGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
presynaptic active zone cytoplasmic componentGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
glutamatergic synapseGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
mitochondrionCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
mitochondrial outer membraneCDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (456)

Assay IDTitleYearJournalArticle
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1576352Thermodynamic solubility of compound in buffer containing KH2PO4/Na2HPO4 with 1% v/v DMSO at pH 7.4 incubated for 24 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID172053Hypolipidemic effects(plasma cholesterol) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID342274Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 60 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 6 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID1220256Total clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID439612Antagonist activity at human T1R2/T1R3 receptor expressed in HEK293E cells assessed as inhibition of sucralose-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID1450594In vivo drug metabolism in human assessed as CYP2C8-mediated gemfibrozil-1-O-beta-glucuronide-2'-benzyl alcohol metabolite levels in urine at 450 mg, po after 24 hrs by HPLC analysis2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID1220255Apparent permeability by PAMPA method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID172029Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID392224Antidyslipidemic activity against triton-induced inhibition of post heparin lipolytic activity in Charles Foster rat hyperlipidemia model assessed as formation of free fatty acid per mL of plasma at 100 mg/kg, po after 18 hrs relative to control2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents.
AID1576351Thermodynamic solubility of compound in buffer containing KH2PO4/Na2HPO4 with 1% v/v DMSO at pH 6.8 incubated for 24 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID22149Solubility ratio ([HbS+drug (5 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1576349Octanol/water partition coefficient, logP of compound by RP-UHPLC analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID342272Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 20 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 6 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID172038Hypolipidemic effects(liver weight) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1576357Kinetic solubility of compound in HDM-PAMPA with buffer containing 5% DMSO at pH 7.4 incubated for 5 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID172037Hypolipidemic effects(liver weight) in male rats at 12.5 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172018Hypolipidemic effects as the ratio of (HDL/LDL) in male rats at dose 25 mg/kg.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1220786Fraction unbound in monkey plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID776250Antidyslipidemic activity in Charles foster rat assessed as decrease in triton WR-1339-induced phospholipid level in plasma at 100 mg/kg, po after 18 hrs relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID392221Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in phospholipid level at 100 mg/kg, po after 18 hrs relative to control2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1220249Activity of human UGT2B7 expressed in insect cells assessed as reduction in compound level after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1220242Unbound intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1220239Unbound intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1220783Drug metabolism in human assessed as glucuronide concentration in bile and urine2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID258534Weight gain in cholesterol-fed male rats at 50 mg/kg/day relative to control2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID1211241Fraction unbound in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1211181Ratio of UGT2B7-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT2B7-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID342267Increase in survival of LPS-induced BALB/c mouse severe systemic infection model at 60 mg/kg, ip administered as single dose 2 hrs before LPS challenge2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID1211218Ratio of unbound intrinsic glucuronidation clearance in human liver microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human liver microsomes in absence of bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID662620Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic rat assessed as decrease in plasma triglyceride level at 100 mg/kg, po relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1220792Ratio of drug level in blood to plasma in dog2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID342283Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 60 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 12 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID189962Hypolipidemic effect on rat plasma Total cholesterol (TC) level by peroral administration at 100 mg/kg dose1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID106805Compound was tested for the inhibition of malate dehydrogenase (MDH) at 200 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID620231Agonist activity at PPARalpha in human HepG2 cells assessed as upregulation of CPT1a mRNA expression at 0.1 to 100 uM after 24 hrs by quantitative RT-PCR analysis2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism.
AID172048Hypolipidemic effects(plasma TG) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID471755Antidyslipidemic activity against triton WR-1339-induced hyperlipidemia in Charles Foster rat assessed as reduction in plasma triglyceride level at 100 mg/kg, po after 18 hrs2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents.
AID169210In vivo biological activity against HDL relative to gemfibrozil in male Sprague-Dawley rats2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Thiourea-based gemfibrozil analogues as HDL-elevating agents.
AID1211279Renal clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1220784Fraction unbound in mouse plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID172050Hypolipidemic effects(plasma TG) in male rats at a dose of 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID342276Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 40 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 8 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID1220241Intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID687687Antidyslipidemic activity in Triton fed hyperlipidemic Charles Foster rat assessed as reduction in plasma total cholesterol at 100 mg/kg, po2012European journal of medicinal chemistry, Nov, Volume: 57Discovery of amide based fibrates as possible antidyslipidemic and antioxidant agents.
AID172054Hypolipidemic effects(plasma cholesterol) in male rats at 12.5 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1810337Agonist activity at human PPARalpha transfected in COS-7 cells assessed luciferase activity measured after 24 hrs by cell based luciferase transactivation assay2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
AID172021Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at 12.5 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID172017Hypolipidemic effects as the ratio of (HDL/LDL) in male rats at dose 12.5 mg/kg.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1220801Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1211285Glucuronidation clearance in human liver microsomes in presence of bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211188Ratio of UGT2B7-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT2B7-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID374047Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in triglyceride level at 100 mg/kg, po after 18 hrs by spectrophotometry relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases.
AID172019Hypolipidemic effects as the ratio of (HDL/LDL) in male rats at dose 50 mg/kg.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID407366Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID172022Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1220238Intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID437265Antihyperlipidemic activity in high-cholesterol diet fed Wistar albino rat model assessed as increase in serum HDL level at 20 mg/kg, po2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs.
AID620228Agonist activity at Gal4-fused PPARalpha expressed in HEK293 cells after 18 hrs by dual luciferase reporter gene assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism.
AID1239061Binding affinity to TTR in human plasma assessed as protein stabilization preincubated for 1 hr followed by urea-mediated denaturation by Western blot analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
AID1218864Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
AID471753Antidyslipidemic activity against triton WR-1339-induced hyperlipidemia in Charles Foster rat assessed as reduction in plasma total cholesterol level at 100 mg/kg, po after 18 hrs2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents.
AID1576358Permeability coefficient of compound in buffer containing 5% DMSO and 100 mM KCl at pH 6.8 incubated for 5 hrs by HDM-PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID437263Antihyperlipidemic activity in high-cholesterol diet fed Wistar albino rat model assessed as reduction in serum total cholesterol level at 20 mg/kg, po2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs.
AID662631Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic rat assessed as increase in LCAT enzyme level at 100 mg/kg, po2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID296527Decrease in total cholesterol level in WR-1339-induced hyperlipidemic rat plasma at 100 mg/kg, po2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Expeditious and convenient synthesis of pregnanes and its glycosides as potential anti-dyslipidemic and anti-oxidant agents.
AID1211174Drug metabolism in human intestinal microsomes assessed as UGT2B7-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1576353Apparent solubility of compound in fasted state simulated intestinal fluid at pH 6.5 by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID753774Antihyperlipidemic activity in triton WR-1339-induced Charles-Foster rat assessed as increase in post heparin lipolytic activity at 100 mg/kg, po after 18 hrs by spectrophotometric analysis relative to control2013European journal of medicinal chemistry, Jun, Volume: 64Coumarin chalcone fibrates: a new structural class of lipid lowering agents.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID626106Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma protein level at 100 mg/kg, po after 18 hrs2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID92255Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 1 x 10 e-3 M2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and antiplatelet activity of gemfibrozil chiral analogues.
AID1221782Cytotoxicity against HEK293 cells expressing UGT assessed as decrease in cell viability at 1 mM measured up to 72 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1261318Selectivity index, ratio of CC50 for MDBK cells to EC50 for BVDV2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1591810Up regulation of ApoA1 mRNA expression in human HepG2 cells at 100 uM by RT-PCR analysis relative to control2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID169209In vivo biological activity against Apo A-I relative to gemfibrozil in male Sprague-Dawley rats2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Thiourea-based gemfibrozil analogues as HDL-elevating agents.
AID186016Hypolipidemic effects in rat fed a high cholesterol diet (HC) by peroral administration at 100 mg/kg dose (increase in liver weight with respect to body weight mg/g)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID662618Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic rat assessed as decrease in plasma total cholesterol level at 100 mg/kg, po relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID172023Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1576350Thermodynamic solubility of compound in buffer containing HCl/KCl with 1% v/v DMSO at pH 1.2 incubated for 24 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID111634In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1261315Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID91211Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 40 mM concentration1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID1211226Drug metabolism in human liver microsomes assessed as UGT2B7-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID770341Antihyperlipidemic activity in triton-induced Charles-Foster rat assessed as increase in plasma lecithin cholesterol acyltransferase activity at 100 mg/kg, po after 18 hrs by colorimetric assay2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID342277Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 60 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 8 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID172036Hypolipidemic effects(liver weight) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1261311Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1770500Activation of full length human sGC alpha1/beta1 subunit containing heme in ferric state expressed in Sf9 insect cells using cGMP as substrate incubated for 15 mins by [32P]GTP assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Gemfibrozil derivatives as activators of soluble guanylyl cyclase - A structure-activity study.
AID662619Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic rat assessed as decrease in plasma phospholipid level at 100 mg/kg, po relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1211248Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID250386Effect on level of triglyceride in (relative to untreated control) in cholesterol fed-male rats at 50 mg/kg/day2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents.
AID258524Increase of total cholesterol level in cholesterol-fed male rats at 50 mg/kg/day relative to control2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID626107Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma post heparin lipolytic activity assessed per mL of plasma at 100 mg/kg, po after 18 hrs2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity.
AID91209Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 20 mM concentration1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID1218865Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
AID1211281Ratio of drug level blood to plasma in human2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1450595In vivo drug metabolism in human assessed as CYP2C8-mediated gemfibrozil-1-O-beta-glucuronide-5'-benzyl alcohol metabolite levels in urine at 450 mg, po after 24 hrs by HPLC analysis2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID1220787Fraction unbound in dog plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220790Ratio of drug level in blood to plasma in rat2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID770359Antihyperlipidemic activity in Charles-Foster rat assessed as reversal of triton-induced increase in plasma phospholipid level at 100 mg/kg, po after 18 hrs relative to control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID776230Antidyslipidemic activity in Charles foster rat assessed as increase in triton WR-1339-reduced lipoprotein lipase level in liver at 100 mg/kg, po relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID1810342Agonist activity at human PPARgamma transfected in COS-7 cells assessed maximum luciferase activity measured after 24 hrs by cell based luciferase transactivation assay relative to rosiglitazone2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
AID172039Hypolipidemic effects(liver weight) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1220240Unbound fraction during CYP4500-mediated metabolism in human intestinal microsomes2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID92093Compound concentration that cause 50% inhibition of human platelet aggregation by COL/EPI cartridges2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and antiplatelet activity of gemfibrozil chiral analogues.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1770502Vasodilation activity in C57Bl6 mouse thoracic aorta assessed as inhibition of phenylephrine-induced contractions2021European journal of medicinal chemistry, Nov-15, Volume: 224Gemfibrozil derivatives as activators of soluble guanylyl cyclase - A structure-activity study.
AID489928Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in triglyceride level at 100 mg/kg, po after 18 hrs by spectrophotometry relative to control2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel coumarin derivatives as potential antidyslipidemic agents.
AID1770501Activation of full length human sGC alpha1/beta1 subunit containing heme in ferric state expressed in Sf9 insect cells using cGMP as substrate incubated for 15 mins at 100 uM incubated for 10 mins by [32P]GTP assay relative to control2021European journal of medicinal chemistry, Nov-15, Volume: 224Gemfibrozil derivatives as activators of soluble guanylyl cyclase - A structure-activity study.
AID172055Hypolipidemic effects(plasma cholesterol) in male rats at 25 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1261316Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID111645In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID299410Agonist activity at human PPARalpha in CV1 cells by GAL4 transactivation assay after 24 hrs2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
AID1211278Clearance in iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID258517Increase of HDL cholesterol in normal-fed rat at 50 mg/kg/day2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID1211259Ratio of UGT2B7-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT2B7-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID705588Reversible inhibition of CYP2C8 in human liver microsomes2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1576348Permeability coefficient of compound in phosphate buffer containing 5% DMSO at pH 7.4 incubated for 7 hrs by HDC/NOPE PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID21143Solubility of Deoxyhemoglobin S (dHbS) concentration after addition dithionite as control1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID481284Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma post heparin lipolytic activity at 100 mg/kg, po after 18 hrs by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Synthesis of novel benzocoumarin derivatives as lipid lowering agents.
AID391554Agonist activity at human PPARgamma ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay relative to rosiglitazone2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1211273Ratio of UGT2B7-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT2B7-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM in presence of 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID396338Antidyslipidemic activity in WR-1339-induced hyperglycemic Charles Foster rat assessed as reduction in plasma cholesterol level at 100 mg/kg, po after 18 hrs2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Novel keto-enamine Schiffs bases from 7-hydroxy-4-methyl-2-oxo-2H-benzo[h] chromene-8,10-dicarbaldehyde as potential antidyslipidemic and antioxidant agents.
AID92256Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 2 x 10 e-3 M2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and antiplatelet activity of gemfibrozil chiral analogues.
AID1323834Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID427201Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID22148Solubility ratio ([HbS+drug (40 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1261312Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID173554Dose administered for testing biological activity in vivo in male Sprague-Dawley rats2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Thiourea-based gemfibrozil analogues as HDL-elevating agents.
AID392222Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in triglyceride level at 100 mg/kg, po after 18 hrs relative to control2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents.
AID374050Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in total cholesterol level at 100 mg/kg, po after 18 hrs by spectrophotometry relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases.
AID776248Antidyslipidemic activity in Charles foster rat assessed as increase in triton WR-1339-reduced post heparin lipolytic activity level in plasma at 100 mg/kg, po after 18 hrs by spectrophotometric analysis relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID1810340Agonist activity at human PPARalpha transfected in COS-7 cells assessed maximum luciferase activity measured after 24 hrs by cell based luciferase transactivation assay relative to gemfibrozil2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
AID489926Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in total cholesterol level at 100 mg/kg, po after 18 hrs by spectrophotometry relative to control2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel coumarin derivatives as potential antidyslipidemic agents.
AID258518Increase of HDL cholesterol in chow-fed hamster at 45 mg/kg/day2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID1220793Ratio of drug level in blood to plasma in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID111629In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID172030Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID437267Antihyperlipidemic activity in high-cholesterol diet fed Wistar albino rat model assessed as ratio of LDL level to HDL level at 20 mg/kg, po2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs.
AID687690Antidyslipidemic activity in Triton fed hyperlipidemic Charles Foster rat assessed as increase in post heparin lipoprotein lipase activity by measuring free fatty acids formation rate per ml of plasma at 100 mg/kg, po2012European journal of medicinal chemistry, Nov, Volume: 57Discovery of amide based fibrates as possible antidyslipidemic and antioxidant agents.
AID485562Antidyslipidemic activity in Charles Foster rat assessed as reduction of Triton WR-1339-induced increase of blood triglyceride level at 100 mg/kg, po after 18 hrs2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
AID1591814Antihyperlipidemic activity in po dosed Sprague-Dawley rat assessed as decrease in triglyceride level administered twice daily for 1 week measured 2 hrs post-last dose by GPO-PAP analysis relative to control2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID1220789Ratio of drug level in blood to plasma in mouse2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID258521Increase of HDL level in cholesterol-fed male rats by ultracentrifugation method at 50 mg/kg/day relative to control2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID1211266Ratio of UGT2B7-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT2B7-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID258525Triglyceride level in cholesterol-fed male rats at 50 mg/kg/day relative to control2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID1576354Apparent solubility of compound in fed state simulated intestinal fluid at pH 5 by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID342263Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as mouse survival at 20 mg/kg, ip administered once daily from day 4 to 10 post viral challenge2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID172047Hypolipidemic effects(plasma TG) in male rats at 12.5 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1239062Half life in plasma (unknown origin)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
AID420695Hypolipidemic activity in 14 days high cholesterol diet fed Wistar albino rat hyperlipidemic model assessed as decrease in serum low density lipoprotein cholesterol level at 20 mg/kg, po administered on day 8 to 142009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID342275Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 20 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 8 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID1220796Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID420694Hypolipidemic activity in 14 days high cholesterol diet fed Wistar albino rat hyperlipidemic model assessed as increase in serum high density lipoprotein cholesterol level at 20 mg/kg, po administered on day 8 to 142009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID503308Antiproliferative activity against human PC3 cells at 30 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1220798Half life in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1576356Kinetic solubility of compound in HDM-PAMPA with buffer containing 5% DMSO at pH 6.8 incubated for 5 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID770361Antihyperlipidemic activity in Charles-Foster rat assessed as reversal of triton-induced increase in plasma total cholesterol level at 100 mg/kg, po after 18 hrs relative to control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID392223Decrease in triton-induced increase in protein level in Charles Foster rat hyperlipidemia model at 100 mg/kg, po after 18 hrs relative to control2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents.
AID687688Antidyslipidemic activity in Triton fed hyperlipidemic Charles Foster rat assessed as reduction in plasma phospholipids at 100 mg/kg, po2012European journal of medicinal chemistry, Nov, Volume: 57Discovery of amide based fibrates as possible antidyslipidemic and antioxidant agents.
AID1323835Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID111637In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID172057Hypolipidemic effects(plasma cholesterol) in male rats at a dose of 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID776252Antidyslipidemic activity in Charles foster rat assessed as decrease in triton WR-1339-induced total cholesterol level in plasma at 100 mg/kg, po after 18 hrs relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID396340Antidyslipidemic activity in WR-1339-induced hyperglycemic Charles Foster rat assessed as reduction in plasma phospholipid level at 100 mg/kg, po after 18 hrs2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Novel keto-enamine Schiffs bases from 7-hydroxy-4-methyl-2-oxo-2H-benzo[h] chromene-8,10-dicarbaldehyde as potential antidyslipidemic and antioxidant agents.
AID396339Antidyslipidemic activity in WR-1339-induced hyperglycemic Charles Foster rat assessed as reduction in plasma triglyceride level at 100 mg/kg, po after 18 hrs2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Novel keto-enamine Schiffs bases from 7-hydroxy-4-methyl-2-oxo-2H-benzo[h] chromene-8,10-dicarbaldehyde as potential antidyslipidemic and antioxidant agents.
AID1220257Ratio of drug level in blood to plasma in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID485561Antidyslipidemic activity in Charles Foster rat assessed as reduction of Triton WR-1339-induced increase of blood phospholipid level at 100 mg/kg, po after 18 hrs2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
AID705607Inhibition of CYP2C82012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1261317Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID503325Activation of c-Jun expressed in HEK293 cells assessed as induction of protein interaction with Pin1 by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID1261340Antiviral activity against HSV12015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID420693Hypolipidemic activity in 14 days high cholesterol diet fed Wistar albino rat hyperlipidemic model assessed as decrease in serum triglyceride level at 20 mg/kg, po administered on day 8 to 142009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID342270Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 40 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 4 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID172028Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at 12.5 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID620229Agonist activity at Gal4-fused PPARalpha expressed in HEK293 cells after 18 hrs by dual luciferase reporter gene assay relative to gemfibrozil2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism.
AID342281Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 20 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 12 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID172033Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at a dose of 50 mg/kg; Compound was screening orally at 50 mg/Kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1211283Fraction metabolized glucuronidation in human liver microsomes in presence of UDP-glucuronosyltransferase and bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID753775Antihyperlipidemic activity in triton WR-1339-induced Charles-Foster rat assessed as decrease in plasma triglyceride level at 100 mg/kg, po after 18 hrs relative to control2013European journal of medicinal chemistry, Jun, Volume: 64Coumarin chalcone fibrates: a new structural class of lipid lowering agents.
AID1261310Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1591809Inhibition of BRD4 bromodomain 2 (unknown origin) incubated for 30 mins by ELISA2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID1576359Permeability coefficient of compound in buffer containing 5% DMSO and 100 mM KCl at pH 7.4 incubated for 5 hrs by HDM-PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID1261314Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID770357Antihyperlipidemic activity in Charles-Foster rat assessed as reversal of triton-induced increase in plasma triglyceride level at 100 mg/kg, po after 18 hrs relative to control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID687691Increase in lipoprotein lipase activity in Triton fed hyperlipidemic Charles Foster rat plasma assessed as free fatty acids formation rate per ml of plasma relative to untreated Triton control2012European journal of medicinal chemistry, Nov, Volume: 57Discovery of amide based fibrates as possible antidyslipidemic and antioxidant agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID190143Hypolipidemic effects of compound on rat plasma Triglyceride (TG) level after peroral administration at 100 mg/kg dose1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID250431Effect on change in body weight gain (relative to untreated control) in cholesterol fed-male rats at 50 mg/kg/day2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents.
AID172020Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1211237Fraction unbound in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID342266Increase in survival of LPS-induced BALB/c mouse severe systemic infection model at 60 mg/kg, ip administered as single dose 1 hr before LPS challenge2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID485560Antidyslipidemic activity in Charles Foster rat assessed as reduction of Triton WR-1339-induced increase of blood total cholesterol level at 100 mg/kg, po after 18 hrs2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1218863Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
AID1211210Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID250825Effect on level of high density lipoprotein cholesterol (relative to untreated control) in cholesterol fed-male rats at 50 mg/kg/day2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents.
AID1211202Drug metabolism in human liver microsomes assessed as UGT2B7-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID170908Percentage change in total cholesterol was determined in vivo in male Sprague-Dawley rats2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Thiourea-based gemfibrozil analogues as HDL-elevating agents.
AID391555Agonist activity at human PPARalpha ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID258520Increase of HDL cholesterol in normal-fed dog at 250 mg/kg/day2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID342273Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 40 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 6 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID342282Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 40 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 12 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID1211239Fraction unbound in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211286Drug metabolism in human kidney microsomes assessed as UGT2B7-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID374051Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in phospholipid level at 100 mg/kg, po after 18 hrs by spectrophotometry relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases.
AID1220785Fraction unbound in rat plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID443179Antidyslipidemic activity against triton-induced inhibition of post heparin lipolytic activity in Charles Foster rat at 100 mg/kg, po after 18 hrs2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents.
AID1261328Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID190101Hypolipidemic effects of compound on rat plasma high density lipoprotein cholesterol (HDLC) level after peroral administration at 100 mg/kg dose1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID299411Agonist activity at human PPARalpha in CV1 cells by GAL4 transactivation assay after 24 hrs relative to gemfibrozil2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID770360Antihyperlipidemic activity in Charles-Foster rat assessed as reversal of triton-induced increase in plasma total cholesterol level at 100 mg/kg, po after 18 hrs relative to triton-treated control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID296529Decrease in triglyceride level in WR-1339-induced hyperlipidemic rat plasma at 100 mg/kg, po2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Expeditious and convenient synthesis of pregnanes and its glycosides as potential anti-dyslipidemic and anti-oxidant agents.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1450596Inhibition of CYP2C8 in human liver microsomes after 15 mins2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID391556Agonist activity at human PPARalpha ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay relative to gemfibrozil2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
AID340947Decrease in intracellular calcium concentration in human THP1 cells at 250 uM after 60 mins2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID1810338Agonist activity at human PPARdelta transfected in COS-7 cells assessed luciferase activity measured after 24 hrs by cell based luciferase transactivation assay2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
AID471754Antidyslipidemic activity against triton WR-1339-induced hyperlipidemia in Charles Foster rat assessed as reduction in plasma phospholipid level at 100 mg/kg, po after 18 hrs2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220797Volume of distribution at steady state in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID172056Hypolipidemic effects(plasma cholesterol) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID250452Effect on level of total cholesterol (relative to untreated control) in cholesterol fed-male rats at 50 mg/kg/day2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents.
AID1261313Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1220259Oral absorption in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220791Ratio of drug level in blood to plasma in monkey2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1211251Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID481281Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma total cholesterol level at 100 mg/kg, po after 18 hrs by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Synthesis of novel benzocoumarin derivatives as lipid lowering agents.
AID753776Antihyperlipidemic activity in triton WR-1339-induced Charles-Foster rat assessed as decrease in plasma phospholipid level at 100 mg/kg, po after 18 hrs relative to control2013European journal of medicinal chemistry, Jun, Volume: 64Coumarin chalcone fibrates: a new structural class of lipid lowering agents.
AID171035Percentage change in total triglycerides was determined in vivo in male Sprague-Dawley rats2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Thiourea-based gemfibrozil analogues as HDL-elevating agents.
AID92258Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 4 x 10 e-3 M2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and antiplatelet activity of gemfibrozil chiral analogues.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID172049Hypolipidemic effects(plasma TG) in male rats at 50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID427202Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID977600pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID296531Decrease in phospholipid level in WR-1339-induced hyperlipidemic rat plasma at 100 mg/kg, po2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Expeditious and convenient synthesis of pregnanes and its glycosides as potential anti-dyslipidemic and anti-oxidant agents.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID443176Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in triglyceride level at 100 mg/kg, po after 18 hrs relative to control2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents.
AID977603pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1220795Plasma clearance in po dosed human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID443177Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in plasma phospholipid level at 100 mg/kg, po after 18 hrs relative to control2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents.
AID184089In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1450583In vivo inhibition of CYP2C8 in human assessed as reduction in gemfibrozil-1-O-glucuronide metabolite formation in plasma at 30 mg/kg, po administered as single dose measured after 10 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID1576355Kinetic solubility of compound in HDM-PAMPA with buffer containing 5% DMSO at pH 1.2 incubated for 5 hrs by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID1220237Unbound fraction during UGT-mediated glucuronidation in human intestinal microsomes2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID91213Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 5 mM concentration1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID342278Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 20 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 10 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID1307966Inhibition of human recombinant COX1 expressed in Sf9 cell microsomes assessed as reduction in conversion of arachidonic acid to PGE2 at 250 uM incubated for 5 mins by HTRF assay2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID342280Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 60 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 10 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID172046Hypolipidemic effects(plasma TG) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1591813Antihyperlipidemic activity in po dosed Sprague-Dawley rat assessed as increase in HDL-C level administered twice daily for 1 week measured 2 hrs post-last dose by HPLC analysis relative to control2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID172027Hypolipidemic effects (high-density lipoprotein (HDL) cholesterol) in male rats at 12.50 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID1239060Binding affinity to TTR (unknown origin) by isothermal titration calorimetric analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID179764In vitro inhibitory activity against rat microsomal lipid peroxidation (m-LPO)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID662628Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic rat assessed as increase in PHLA enzyme level at 100 mg/kg, po2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1211220Ratio of unbound intrinsic glucuronidation clearance in human kidney microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human kidney microsomes in absence of bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481283Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma triglyceride level at 100 mg/kg, po after 18 hrs by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Synthesis of novel benzocoumarin derivatives as lipid lowering agents.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID258519Increase of HDL cholesterol in normal-fed hamster at 45 mg/kg/day2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID342264Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as mouse survival at 40 mg/kg, ip administered once daily from day 4 to 10 post viral challenge2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID705589Reversible inhibition of CYP2C9 in human liver microsomes2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1261308Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID540235Phospholipidosis-negative literature compound
AID770356Antihyperlipidemic activity in Charles-Foster rat assessed as reversal of triton-induced increase in plasma triglyceride level at 100 mg/kg, po after 18 hrs relative to triton-treated control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID626105Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma phospholipid level at 100 mg/kg, po after 18 hrs2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity.
AID1261309Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID753777Antihyperlipidemic activity in triton WR-1339-induced Charles-Foster rat assessed as decrease in plasma total cholesterol level at 100 mg/kg, po after 18 hrs relative to control2013European journal of medicinal chemistry, Jun, Volume: 64Coumarin chalcone fibrates: a new structural class of lipid lowering agents.
AID620230Selectivity ratio of EC50 for Gal4-fused PPARalpha expressed in HEK293 cells to EC50 for Gal4-fused PPARgamma expressed in HEK293 cells2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism.
AID443178Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in plasma triglyceride level at 100 mg/kg, po after 18 hrs relative to control2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents.
AID299412Agonist activity at human PPARgamma in CV1 cells by GAL4 transactivation assay after 24 hrs2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
AID22012Solubility ratio ([HbS+drug (10 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID91208Antigelling activity expressed as ratio of soluble sickle hemoglobin (HbS) of compound (g/dL) and that of control at 10 mM concentration.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
AID1221780Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID420696Ratio of serum LDL cholesterol to serum HDL cholesterol in 14 days high cholesterol diet fed Wistar albino rat at 20 mg/kg, po administered on day 8 to 142009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID1211233Drug metabolism in human kidney microsomes assessed as UGT2B7-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID770358Antihyperlipidemic activity in Charles-Foster rat assessed as reversal of triton-induced increase in plasma phospholipid level at 100 mg/kg, po after 18 hrs relative to triton-treated control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID626103Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma total cholesterol level at 100 mg/kg, po after 18 hrs2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity.
AID1220800Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID250629Effect on level of apolipoprotein (Apo) AI (relative to untreated control) in cholesterol fed-male rats at 50 mg/kg/day2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1220788Fraction unbound in human plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID407369Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID1221821Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1211282Fraction metabolized glucuronidation in human liver microsomes in presence of UDP-glucuronosyltransferase2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211245Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID481282Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma phospholipid level at 100 mg/kg, po after 18 hrs by spectrophotometric analysis2010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Synthesis of novel benzocoumarin derivatives as lipid lowering agents.
AID1450593In vivo drug metabolism in human assessed as UGT2B7-mediated gemfibrozil-1-O-beta-glucuronide metabolite levels in urine at 450 mg, po after 24 hrs by HPLC analysis2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID111649liver weight in Wistar-Imamichi rats at 300 mg/kg dose in 12 rats1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1261326Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID489927Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in phospholipid level at 100 mg/kg, po after 18 hrs by spectrophotometry relative to control2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel coumarin derivatives as potential antidyslipidemic agents.
AID299413Agonist activity at human PPARgamma in CV1 cells by GAL4 transactivation assay after 24 hrs relative to rosiglitazone2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
AID1220799Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID258523Increase of Apo A-I level in cholesterol-fed male rats at 50 mg/kg/day relative to control2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID420692Hypolipidemic activity in 14 days high cholesterol diet fed Wistar albino rat hyperlipidemic model assessed as decrease in serum total cholesterol level at 20 mg/kg, po administered on day 8 to 142009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID626104Antihyperlipidemic activity in Charles Foster rat assessed as reduction of triton WR-1339-induced plasma triglyceride level at 100 mg/kg, po after 18 hrs2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Synthesis of novel N-(2-hydroxy-2-p-tolylethyl)-amide and N-(2-oxo-2-p-tolylethyl)-amide derivatives and their antidyslipidemic and antioxidant activity.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID342269Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 20 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 4 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID21145Solubility of Haemoglobin S (HbS) concentration after addition of acid and dithionite1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID374052Antidyslipidemic activity in Charles Foster rat hyperlipidemia model assessed as suppression of triton-induced post heparin lipolytic activity at 100 mg/kg, po after 18 hrs by spectrophotometry relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases.
AID391553Agonist activity at human PPARgamma ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1576360Permeability coefficient of compound in phosphate buffer containing 0.5% DMSO at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID770354Antihyperlipidemic activity in Charles-Foster rat assessed as post heparin lipolytic activity at 100 mg/kg, po after 18 hrs by spectrophotometric analysis relative to triton-treated control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID1220254Bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID1211213Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211280Fraction unbound in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211215Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID258522Increase of HDL level in cholesterol-fed male rats by FPLC method at 50 mg/kg/day relative to control2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
AID1211243Fraction unbound in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID342268Toxicity in mouse assessed as lethal dose2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID1220794Plasma clearance in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID84868The compound was evaluated for its ability to reduce liver cholesterol esters(LCE) in cholesterol-fed hamsters; NE=no effect at 100 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID687689Antidyslipidemic activity in Triton fed hyperlipidemic Charles Foster rat assessed as reduction in plasma triglyceride level at 100 mg/kg, po2012European journal of medicinal chemistry, Nov, Volume: 57Discovery of amide based fibrates as possible antidyslipidemic and antioxidant agents.
AID111620Hypotriglyceridemic activity of KK-mice in 12 animals1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID705609Plasma concentration in human after 12 hrs2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID776249Antidyslipidemic activity in Charles foster rat assessed as decrease in triton WR-1339-induced triglyceride level in plasma at 100 mg/kg, po after 18 hrs relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID342271Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 60 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 4 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID22013Solubility ratio ([HbS+drug (20 mM)]/[HbS-drug]1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1211195Ratio of UGT2B7-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT2B7-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID186025Hypolipidemic effects in rat fed a normal diet by peroral administration at 100 mg/kg dose.(increase in liver weight with respect to body weight mg/g)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID1211284Glucuronidation clearance in human liver microsomes2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211253Drug metabolism in human intestinal microsomes assessed as UGT1A9-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1810339Agonist activity at human PPARgamma transfected in COS-7 cells assessed luciferase activity measured after 24 hrs by cell based luciferase transactivation assay2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
AID342265Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as mouse survival at 60 mg/kg, ip administered once daily from day 4 to 10 post viral challenge2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID92259Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 5 x 10 e-3 M2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and antiplatelet activity of gemfibrozil chiral analogues.
AID172025Hypolipidemic effects (Low-density lipoprotein (LDL) cholesterol) in male rats at a dose of 50 mg/kg; Compound was screening orally at 50 mg/Kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1211222Ratio of unbound intrinsic glucuronidation clearance in human intestinal microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human intestinal microsomes in absence of bovine serum albumin2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1220258Renal clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
AID342279Antiviral activity against Influenza A virus (A/Japan/305/57(H2N2)) infected BALB/c mouse assessed as infection-induced weight loss at 40 mg/kg, ip administered once daily from day 4 to 10 post viral challenge measured on day 10 postinfection2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Increased survival after gemfibrozil treatment of severe mouse influenza.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID392492Antidyslipidemic activity against triton-induced hyperlipidemia in Charles Foster rat assessed as reduction in total cholesterol level at 100 mg/kg, po after 18 hrs relative to control2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents.
AID92257Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 3 x 10 e-3 M2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and antiplatelet activity of gemfibrozil chiral analogues.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID770355Antihyperlipidemic activity in Charles-Foster rat assessed as post heparin lipolytic activity at 100 mg/kg, po after 18 hrs by spectrophotometric analysis relative to control2013European journal of medicinal chemistry, Oct, Volume: 68Hybrid benzofuran-bisindole derivatives: new prototypes with promising anti-hyperlipidemic activities.
AID437264Antihyperlipidemic activity in high-cholesterol diet fed Wistar albino rat model assessed as reduction in serum triglyceride level at 20 mg/kg, po2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism.
AID1345178Human OATP1B1 (SLCO family of organic anion transporting polypeptides)2007Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 35, Issue:8
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,409)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990143 (10.15)18.7374
1990's467 (33.14)18.2507
2000's460 (32.65)29.6817
2010's288 (20.44)24.3611
2020's51 (3.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 89.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index89.87 (24.57)
Research Supply Index7.52 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index164.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (89.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials359 (24.21%)5.53%
Reviews158 (10.65%)6.00%
Case Studies121 (8.16%)4.05%
Observational3 (0.20%)0.25%
Other842 (56.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Exploration of Gemfibrozil as a Treatment for Alcohol Use Disorder [NCT03539432]Phase 23 participants (Actual)Interventional2018-05-16Terminated(stopped due to Funds for the study expired)
Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil) [NCT01376232]Phase 123 participants (Actual)Interventional2010-11-08Completed
A Phase 1, Open-Label, Fixed-sequence, 5-part, Drug-drug Interaction Study of Tucatinib to Evaluate the Effects of CYP3A4 and CYP2C8 Inhibition and Induction on the Pharmacokinetics of Tucatinib and to Evaluate the Effects of Tucatinib on the Pharmacokine [NCT03723395]Phase 1116 participants (Actual)Interventional2018-09-17Completed
A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions [NCT05959447]Phase 136 participants (Anticipated)Interventional2023-08-31Not yet recruiting
A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656 [NCT01083212]Phase 119 participants (Actual)Interventional2010-03-31Completed
A Phase 2, Double-Blind, Multi-Center, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of FHL-301 in Adult Patients With Parkinson's Disease [NCT05931484]Phase 232 participants (Anticipated)Interventional2023-11-01Not yet recruiting
A Phase 1, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effect of the Modulators of the Cytochrome P450 (CYP) 2C8 and/or 3A on the Single-Dose Pharmacokinetics of Ozanimod and CC112273 in Healthy Adult Subjects [NCT03624959]Phase 1100 participants (Actual)Interventional2018-06-20Completed
A Double-Blind, Placebo-Controlled Study to Assess the Effect of Gemfibrozil Co-Administration on the Pharmacokinetics and Pharmacodynamics of Mitiglinide in Healthy Volunteers [NCT00566865]Phase 114 participants (Actual)Interventional2007-11-30Completed
A Four-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin, the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on the Repeat Dose Pharmacokinetics of GSK2118436, and the R [NCT01340846]Phase 148 participants (Actual)Interventional2012-09-03Completed
A Phase 1, 3-arm, Open-label, Sequential Design Study to Investigate the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on Single-dose Pharmacokinetics of BMS-986278 in Healthy Participants [NCT05932303]Phase 147 participants (Actual)Interventional2023-07-12Completed
A Phase 1, Single-center, Open-label, Two-cohort, Two-period, One-sequence, Two Treatment, Drug-drug Interaction Study of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Subjects [NCT06064539]Phase 130 participants (Actual)Interventional2020-05-18Completed
An Open-Label, Randomized, Parallel-Group Drug-Drug Interaction Study to Assess the Effect of Multiple Doses of Itraconazole or Gemfibrozil on the Pharmacokinetics of a Single Dose of JNJ-56021927 in Healthy Male Subjects [NCT02230033]Phase 145 participants (Actual)Interventional2014-09-30Completed
A Three-part, Single-center, Open-label, Phase I Drug-drug Interaction Clinical Study to Investigate the Effect of Itraconazole, Gemfibrozil or Rifampicin on Pharmacokinetics of SKLB1028 in Healthy Subjects [NCT05069870]Phase 142 participants (Actual)Interventional2021-06-07Active, not recruiting
An Open-Label, Nonrandomized Study To Evaluate The Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, A Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally To Healthy Young Adult Subjects [NCT00966966]Phase 117 participants (Actual)Interventional2009-09-30Completed
A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease [NCT04637282]Phase 339 participants (Anticipated)Interventional2023-12-01Not yet recruiting
A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study With Omaveloxolone in Healthy Subjects [NCT04008186]Phase 161 participants (Actual)Interventional2019-06-14Completed
A Relative Bioequivalence Study of 600 mg Gemfibrozil Tablets Under Fasting Conditions [NCT00800475]Phase 140 participants (Actual)Interventional2005-07-31Completed
Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects [NCT01385020]Phase 412 participants (Anticipated)Interventional2011-07-31Completed
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease [NCT02045056]Early Phase 172 participants (Actual)Interventional2014-05-31Completed
A Phase I Randomized, Open-label, 3-arm Parallel-design Study to Determine the Effect of Multiple-dose Gemfibrozil or Itraconazole on the Pharmacokinetics, Safety and Tolerability of Single-dose MDV3100 (ASP9785) in Healthy Male Subjects [NCT01913379]Phase 141 participants (Actual)Interventional2011-08-31Completed
Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques: a Randomised Microarray-Study on Endarterectomy Specimens of Human Carotid Arteries [NCT00243672]Phase 4100 participants (Anticipated)Interventional2005-10-31Withdrawn(stopped due to The study chair changed his employment, the realization of the study was not possible)
A Phase 1, Single-Center, Parallel-Group, Open-Label, Randomized, Drug-Drug Interaction Study to Assess the Effect of Itraconazole, Phenytoin, and Gemfibrozil on the Pharmacokinetics of a Single Oral Dose of BMS-986166 in Healthy Participants [NCT04956627]Phase 115 participants (Actual)Interventional2021-07-28Completed
A Single-center, Open-label, Randomized, Two-part, Two-treatment, Two-period Crossover Study to Investigate the Effect of Gemfibrozil or Rifampicin on the Pharmacokinetics of Selexipag and Its Metabolite ACT-333679 in Healthy Male Subjects. [NCT02770222]Phase 140 participants (Actual)Interventional2016-06-30Completed
An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide [NCT01797198]Phase 148 participants (Actual)Interventional2012-04-30Completed
Relative Bioavailability of Single Dose BI 10773 Co-administered With Multiple Doses of 600 mg Gemfibrozil Bid Compared to Single Dose Treatment of BI 10773 Alone in Healthy Volunteers - a Phase I, Open-label, Randomised, 2-way Crossover Trial [NCT01301742]Phase 118 participants (Actual)Interventional2011-02-28Completed
Effect of Gemfibrozil on Serum GPI Phospholipase D and Triglycerides [NCT00108511]Phase 10 participants Interventional2004-10-31Completed
[NCT00000461]Phase 20 participants Interventional1986-12-31Completed
Endothelial Dysfunction as a Risk Factor in HIV Study [NCT00039663]Phase 175 participants Interventional2002-05-31Completed
CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol [NCT00283335]Phase 32,531 participants (Actual)Interventional1991-06-30Completed
Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects [NCT01736254]Phase 124 participants (Actual)Interventional2012-12-31Completed
Gemfibrozil for Nicotine Smoking Cessation [NCT02638597]Phase 216 participants (Actual)Interventional2015-02-28Completed
The Influence of Lopinavir/Ritonavir on Gemfibrozil Pharmacokinetics in Healthy Volunteers [NCT00474201]15 participants (Actual)Interventional2007-05-31Completed
Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil, Ketoconazole, and Clarithromycin as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects [NCT01836198]Phase 130 participants (Actual)Interventional2013-05-31Completed
Testing the PPAR Hypothesis of Nicotine Dependence in Humans: Gemfibrozil as a Novel Treatment for Tobacco Addiction [NCT01876810]Phase 228 participants (Actual)Interventional2014-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00474201 (1) [back to overview]Gemfibrozil Area Under the Concentration vs. Time Curve (AUC)
NCT01301742 (3) [back to overview]Total Empa: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01301742 (3) [back to overview]Total Empa: Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)
NCT01301742 (3) [back to overview]Total Empa: Maximum Measured Concentration (Cmax)
NCT01736254 (6) [back to overview]Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil
NCT01736254 (6) [back to overview]Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib
NCT01736254 (6) [back to overview]Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib
NCT01736254 (6) [back to overview]Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil
NCT01736254 (6) [back to overview]Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib
NCT01736254 (6) [back to overview]Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil
NCT01836198 (2) [back to overview]Pharmacokinetics: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of LY2409021
NCT01836198 (2) [back to overview]Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021
NCT01876810 (3) [back to overview]Cue- Reactivity Visual Analogue Scale for Craving After 1 Week of Treatment
NCT01876810 (3) [back to overview]Number of Days With Self-report of No Smoking and Breath Carbon Monoxide of <5 PPM During Quit-attempt Weeks
NCT01876810 (3) [back to overview]The Percentage of Choice of Nicotinized Cigarettes After 1 Week of Treatment
NCT02638597 (2) [back to overview]Exhaled Carbon Monoxide (CO)
NCT02638597 (2) [back to overview]Heaviness of Smoking Index
NCT03539432 (6) [back to overview]Mean Standard Drinks Per Drinking Day
NCT03539432 (6) [back to overview]Mean Standard Drinks Per Drinking Day
NCT03539432 (6) [back to overview]Mean Standard Drinks Per Drinking Day
NCT03539432 (6) [back to overview]Percent Days Abstinent
NCT03539432 (6) [back to overview]Percent Days Abstinent
NCT03539432 (6) [back to overview]Percent Days Abstinent

Gemfibrozil Area Under the Concentration vs. Time Curve (AUC)

AUC (ng*hr/mL) of gemfibrozil when given as a 600 mg dose by itself compared to gemfibrozil AUC after 14.5 days of lopinavir-ritonavir (400mg/100mg) twice daily. (NCT00474201)
Timeframe: 22 days per subject (approximately 1 year for entire study completion)

Interventionng*hr/mL (Geometric Mean)
Gemfibrozil Alone (Control Group)104
Gemfibrozil + Lopinavir-ritonavir62

[back to top]

Total Empa: Area Under the Curve 0 to Infinity (AUC0-∞)

"Area under the plasma concentration-time curve of the analyte from time 0 extrapolated to infinity.~The standard deviation presented in the analysis is actually the intra-individual geometric standard deviation (gCV)." (NCT01301742)
Timeframe: 0 minutes (min), 20 min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 23h, 36h, 47h, 71h after the first dose

Interventionnmol*h/L (Geometric Mean)
Empa Alone4708.33
Empa and Gemfibrozil7462.74

[back to top]

Total Empa: Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)

"Area under the plasma concentration-time curve of the analyte from time 0 to the time of the last quantifiable data point.~The standard deviation presented in the analyses is actually the intra-individual geometric standard deviation (gCV)." (NCT01301742)
Timeframe: 0 minutes (min), 20 min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 23h, 36h, 47h, 71h after the first dose

Interventionnmol*h/L (Geometric Mean)
Empa Alone4643.81
Empa and Gemfibrozil7350.84

[back to top]

Total Empa: Maximum Measured Concentration (Cmax)

"Maximum measured concentration of total Empagliflozin (Empa) in plasma, per period.~The standard deviation presented in the analysis is actually the intra-individual geometric standard deviation (gCV)." (NCT01301742)
Timeframe: 0 minutes (min), 20min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 23h, 36h, 47h, 71h after the first dose

Interventionnmol/L (Geometric Mean)
Empa Alone602.24
Empa and Gemfibrozil692.59

[back to top]

Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil

Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib. (NCT01736254)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13

Interventionng*h/mL (Geometric Mean)
Gemfibrozil55700
Evacetrapib + Gemfibrozil53800

[back to top]

Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib

Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil. (NCT01736254)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22

Interventionnanograms*hours/milliliter (ng*h/mL) (Geometric Mean)
Evacetrapib11300
Evacetrapib + Gemfibrozil11400

[back to top]

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib

Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil. (NCT01736254)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22

Interventionnanograms/milliliter (ng/mL) (Geometric Mean)
Evacetrapib1270
Evacetrapib + Gemfibrozil1290

[back to top]

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil

Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib. (NCT01736254)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13

Interventionng/mL (Geometric Mean)
Gemfibrozil17400
Evacetrapib + Gemfibrozil16800

[back to top]

Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib

Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil. (NCT01736254)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22

Interventionhours (Median)
Evacetrapib4.00
Evacetrapib + Gemfibrozil3.00

[back to top]

Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil

Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib. (NCT01736254)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13

Interventionhours (Median)
Gemfibrozil1.00
Evacetrapib + Gemfibrozil1.08

[back to top]

Pharmacokinetics: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of LY2409021

(NCT01836198)
Timeframe: Predose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 216, and 336 hours postdose (and 408, 504, and 576 hours postdose in Part A, Period 2 and Part B only)

Interventionnanogram*hours per milliliter (ng*h/mL) (Geometric Mean)
LY2409021 Only (Part A, Cohort 1)34700
LY2409021+Gemfibrozil (Part A, Cohort 1)35300
LY2409021 Only (Part A, Cohort 2)38000
LY2409021+Ketoconazole (Part A, Cohort 2)145000
LY2409021 Only (Part B Participants, Data From Part A)37400
LY2409021+Clarithromycin (Part B)43900

[back to top]

Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021

(NCT01836198)
Timeframe: Predose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 216, and 336 hours postdose (and 408, 504, and 576 hours postdose in Part A, Period 2 and Part B only)

Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
LY2409021 Only (Part A, Cohort 1)431
LY2409021+Gemfibrozil (Part A, Cohort 1)410
LY2409021 Only (Part A, Cohort 2)445
LY2409021+Ketoconazole (Part A, Cohort 2)471
LY2409021 Only (Part B Participants, Data From Part A)419
LY2409021+Clarithromycin (Part B)467

[back to top]

Cue- Reactivity Visual Analogue Scale for Craving After 1 Week of Treatment

In this study, each session started with participants taking four puffs of their preferred-brand cigarette to standardize the time from last nicotine exposure. Participants were then seated in a comfortable chair and completed the baseline Visual Analogue Scale for craving 0-100 mm (The higher the number the more is the craving). The smoking cue was a pack of cigarettes and a lighter. Participants were instructed to light the cigarette without puffing and hold it for 30 sec while the physiological recordings were measured. Then the participant was asked to extinguish the cigarette. The neutral cue was an unsharpened pencil, a notepad, and a sharpener. Participants were instructed to sharpen the pencil and hold it as if writing for 30 sec. Participants completed the Visual Analogue Scale for craving during the cue, and 15 and 30 min after cue presentation. (NCT01876810)
Timeframe: during the lab Cue- reactivity paradigm after 1 week of treatment

Interventionunits on a scale: from 0-100 mm (Mean)
Gemfibrozil51
Placebo Group44

[back to top]

Number of Days With Self-report of No Smoking and Breath Carbon Monoxide of <5 PPM During Quit-attempt Weeks

the number of days of no smoking was calculated for each participant. Abstinence was verified by daily Self-reports of no smoking and breath carbon monoxide < 5 ppm (NCT01876810)
Timeframe: 1 week in each phase

Interventiondays (Mean)
Gemfibrozil0.2
Placebo0

[back to top]

The Percentage of Choice of Nicotinized Cigarettes After 1 Week of Treatment

"Percentage of choice of Nicotinized cigarettes was calculated for each participant during the lab session which took place after 1 week of treatment.~Each session started with participants taking four puffs of their preferred-brand cigarette to standardize the time from last nicotine exposure. Participants were asked to complete some questionnaires at baseline. Then, they were asked to relax for 30 min listening to music or reading. Four exposure trials followed that were separated by 30 min of relaxation. In each exposure trial, participants took four puffs of a Nicotinized (A) or Denicotinized (less than 0.05 mg nicotine.) (B) cigarette in the order of ABAB or BABA. Cigarettes were color-coded. Participants then began four choice trials separated by 30 min of relaxation. In each trial, participants chose any combination of 4 puffs from the two cigarettes." (NCT01876810)
Timeframe: during the lab forced choice paradigm after 1 week of treatment

Interventionpercentage of choice of nicotinized ciga (Mean)
Gemfibrozil0.775
Placebo Group0.77

[back to top]

Exhaled Carbon Monoxide (CO)

Exhaled carbon monoxide change from baseline to last available visit. (NCT02638597)
Timeframe: 8 weeks after target quit date

InterventionParts p/million (Mean)
Gemfibrozil10.88
Waitlist21.63

[back to top]

Heaviness of Smoking Index

The outcome measure was Heaviness of Smoking Index at exit. The Heaviness of Smoking Index is a two-item scale, with scores on each item rated on a 1-4 likert scale. The total score of the measure ranges from 2-8, with higher scores indicating worse outcome. (NCT02638597)
Timeframe: 8 weeks after target quit date

Interventionscore on a scale (Mean)
Waitlist1.25
Gemfibrozil1.63

[back to top]

Mean Standard Drinks Per Drinking Day

Average number of standard drinks consumed on drinking days (NCT03539432)
Timeframe: 2 weeks post baseline

InterventionDrinks per drinking day (Mean)
Gemfibrozil4.12

[back to top]

Mean Standard Drinks Per Drinking Day

Average number of standard drinks consumed on drinking days (NCT03539432)
Timeframe: 4 weeks post baseline

InterventionDrinks per drinking day (Mean)
Gemfibrozil2.18

[back to top]

Mean Standard Drinks Per Drinking Day

Average number of standard drinks consumed on drinking days (NCT03539432)
Timeframe: Baseline

InterventionDrinks per drinking day (Mean)
Gemfibrozil6.17
Placebo8.59

[back to top]

Percent Days Abstinent

Percentage of days of abstinence from alcohol (NCT03539432)
Timeframe: 2 weeks post baseline

InterventionPercentage of abstinent days (Mean)
Gemfibrozil45.5

[back to top]

Percent Days Abstinent

Percentage of days of abstinence from alcohol (NCT03539432)
Timeframe: 4 weeks post baseline

InterventionPercentage of abstinent days (Mean)
Gemfibrozil45

[back to top]

Percent Days Abstinent

Percentage of days of abstinence from alcohol (NCT03539432)
Timeframe: Baseline

InterventionPercentage of abstinent days (Mean)
Gemfibrozil31
Placebo32.2

[back to top]